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ABSTRACT OF THE DISSERTATION 
 
Understanding the cellular heterogeneity of fetal-like and adult tissues to study cell-type-
specific functional genetic variation 
 
by 
 
Margaret Kathleen Rose Donovan 
 
Doctor of Philosophy in Bioinformatics and Systems Biology with a Specialization in 
Biomedical Informatics 
 
University of California San Diego, 2019 
 
Professor Kelly A. Frazer, Chair 
 
Genome-wide association studies (GWAS) have suggested that the underlying 
genetic basis of complex traits and disease is driven by large numbers of non-coding 
variants with modest effects that likely act by modifying gene regulation. Towards 
understanding the regulatory impact of genetic variation, expression quantitative trait loci 
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(eQTL) analyses have been performed across dozens of human tissues to link the 
influence of genetic variants on gene expression levels. While these eQTL studies have 
provided important biological insights, they are still limited by not considering the 
contexts in which these variants function, including the stage of development and cell 
type. Specifically, others have shown increased disease risk in adulthood has links to fetal 
origins, suggesting that characterizing gene expression in fetal-like cells could identify 
genetic variants that are associated with adult traits, but function primarily or solely 
during development. Additionally, as eQTL studies are typically performed across bulk 
tissues, unaccounted for cellular heterogeneity present in bulk gene expression 
measurements can affect genotype-gene expression associations. Thus, it is important to 
identify regulatory variants that alter gene expression in both primitive and adult cell 
types and to characterize cellular heterogeneity across tissues to comprehensively 
understand the genetic basis of complex traits and disease. 
Here, I present two studies, which utilize gene expression data from fetal-like and 
adult tissues to characterize cellular heterogeneity at distinct stages of human 
development. I have examined the cellular heterogeneity in fetal-like induced pluripotent 
stem cell (iPSC)-derived cardiovascular progenitor cells (CVPCs) using single cell 
(sc)RNA-seq data to identify cell populations that emerge as a result of the cardiac 
differentiation. Further, I deconvoluted 180 iPSC-CVPCs and identified factors innate to 
iPSCs that impacted cardiac fate. Next, I showed that mouse scRNA-seq can be used as 
an alternative to human scRNA-seq for the deconvolution of adult GTEx bulk tissues and 
considering cell composition eQTL studies powered the discovery of novel eQTLs, some 
of which were cell-type-associated and colocalized with GWAS disease loci.  
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Chapter 1: Association of human iPSC gene signatures and X 
chromosome dosage with two distinct cardiac differentiation 
trajectories 
 
 
1.1 Abstract 
 
Despite the importance of understanding how variability due to non-genetic 
factors (clone and passage) influences iPSC differentiation outcome, large-scale studies 
capable of addressing this question have not yet been conducted. Here, we performed 232 
directed differentiations of 191 iPSC lines to generate iPSC-derived cardiovascular 
progenitor cells (iPSC-CVPCs). We observed cellular heterogeneity across the iPSC-
CVPC samples due to varying fractions of two cell types: cardiomyocytes (CMs) and 
epicardium-derived cells (EPDCs). Comparing the transcriptomes of CM-fated and 
EPDC-fated iPSCs, we discovered that 91 signature genes and X chromosome dosage 
differences are associated with these two distinct cardiac developmental trajectories. In 
an independent set of 39 iPSCs differentiated into CMs, we confirmed that sex and 
transcriptional differences impact cardiac fate outcome. Our study provides novel 
insights into how iPSC transcriptional and X chromosome gene dosage differences 
influence their response to differentiation stimuli and hence cardiac cell fate. 
 
1.2 Introduction 
 
Variability in human induced pluripotent stem cell (iPSC) lines compromises 
their utility for regenerative medicine and as a model system for genetic studies. This 
variability impacts iPSC differentiation outcome and despite using standardized 
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differentiation protocols, results in the generation of samples with cellular heterogeneity 
(i.e. multiple cell types are present within a given sample and the proportions of cell 
types vary across samples). Previous large-scale quantitative trait loci (QTL) studies in 
iPSCs 1,2 have shown that genetic variation accounts for the majority of expression 
differences between iPSC lines, but non-genetic (i.e., clonality and passage) factors also 
contribute to these differences 3. Understanding how non-genetic transcriptional 
differences between iPSC lines impact their differentiation outcome is necessary to 
improve the ability to generate cell types of interest. 
Well-established small molecule protocols for generating iPSC-derived 
cardiovascular progenitor cells (iPSC-CVPCs) 4 produce fetal-like cardiomyocytes, 
which can undergo further specification as cells mature in culture into various cardiac 
subtypes (atrial, ventricular, or nodal) 5. Based on variable cardiac troponin T (cTnT) 
staining, the derived samples are known to display cellular heterogeneity 6,7, but the 
origin of the cTnT-negative non-myocyte cells, and whether the same or different non-
myocyte cell types are consistently derived alongside cTnT-positive myocytes across 
samples has not previously been investigated. The differentiation protocol is dependent 
on manipulation of WNT signaling, initially through activation of the pathway by GSK3 
inhibition, followed by inhibition of the pathway by Porcupine (PORCN) inhibition 8,9. 
An in-depth analysis of the outcomes of independent differentiations of hundreds of iPSC 
lines with different genetic backgrounds could provide insights into the origins of the 
non-myocyte cells, as well as the extent to which non-genetic transcriptional differences 
between iPSC lines contribute to the iPSC-CVPC cellular heterogeneity.  
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Here, we used a highly standardized and systematic approach to conduct 232 
directed differentiations of 191 iPSC lines into iPSC-CVPCs. We characterized the 
cellular heterogeneity of the iPSC-CVPC samples and showed that only two distinct cell 
types were present, cardiomyocytes (CMs) and epicardium-derived cells (EPDCs), which 
varied in proportion across samples. As differentiation protocols to derive iPSC-CMs and 
iPSC-EPDCs primarily differ by a step involving WNT inhibition to derive the former, 
but not the latter 10,11, we hypothesized that the observed cellular heterogeneity could 
result from suboptimal WNT inhibition in subsets of cells across iPSC lines. To test this 
hypothesis, we analyzed transcriptional differences between iPSC lines that differentiated 
into CMs and those that differentiated into EPDCs (e.g. iPSCs with a CM-fate or EPDC-
fate) and discovered 91 signature genes associated with these two distinct cardiac 
differentiation trajectories. These signature genes are involved in differentiation, 
including the Wnt/β-catenin pathway, muscle differentiation or cardiac-related functions, 
and the transition of epicardial cells to EPDCs by epithelial-mesenchymal transition 
(EMT). While the proportion of variance explained by each of the signature genes varied 
over three orders of magnitude, altogether they captured approximately half of the total 
variance underlying iPSC fate determination. Additionally, we show variability in X 
chromosome gene dosage (XactiveXactive vs XactiveXinactive vs XY) across iPSCs plays a role 
in cardiac fate determination. The association with X chromosome gene dosage could in 
part be due to higher expression in CM-fated iPSCs of chrXp11 genes, which encodes 
ELK1 and PORCN. Transcriptomic analysis of an independent set of 39 iPSCs 
differentiated to the cardiac lineage using a similar small molecule protocol 12 confirmed 
our findings. 
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1.3 Results 
 
1.3.1 iPSC-CVPCs show cellular heterogeneity across samples  
To gain insights into molecular mechanisms that could influence variability in 
human iPSC differentiation outcome, we employed a highly systematic approach to 
differentiate 191 pluripotent lines from 181 iPSCORE individuals (Figure 1.1a) into 
iPSC-derived cardiovascular progenitor cells (iPSC-CVPCs). We used a small molecule 
cardiac differentiation protocol used to derive cardiomyocytes 13 followed on D15 by 
lactate selection to obtain pure cardiac cells 14. In total, we conducted 232 
differentiations, of which 193 (83.2%, from 154 lines derived from 144 subjects) were 
completed, i.e. reached Day 25 of differentiation, while 39 (from 37 lines derived from 
37 subjects) were terminated prior to Day 25, because they did not form a syncytial 
beating monolayer (Table 1.1). The completed iPSC-CVPCs at D25 on average had a 
high fraction of cells that stained positive for cardiac troponin T (%cTnT, median = 
89.2%; Figure 1.1b) and were positive by immunofluorescence (IF) for cardiac markers 
(Figures 1.1c-f); however, 15 lines had %cTnT < 40%, indicating that despite lactate 
selection, there was substantial cellular heterogeneity within and across samples. 
  
Table 1.1 Table describing the number of lines and subjects 
for each attempted differentiation 
Cell type 
Number of 
differentiations 
Number 
of lines 
Number of 
subjects 
iPSC 232 191 181 
Terminated 
iPSC-CVPC 
39 37 37 
D25 iPSC-
CVPC 
193 154 144 
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Figure 1.1 Characterization of cellular heterogeneity in iPSC-CVPC samples 
(A) Overview of the study design. Skin fibroblasts from 181 subjects were reprogrammed to 
iPSCs and differentiated to iPSC-CVPCs (191 lines, 232 differentiations). After WNT pathway 
activation at day 0 (D0) and its inactivation by IWP-2 at D3-5, cells differentiate to 
cardiomyocytes (CMs) if the WNT signaling is successfully inhibited. If WNT signaling is not 
sufficiently inhibited, cells differentiate to EPDCs. 193 of the 232 differentiations were completed 
(D25), and we observed that different CVPC samples had different proportions of CMs and 
EPDCs. (B) Distribution of %cTnT. Dashed redline represents the median value. (C-E) 
Immunofluorescence staining of (C) iPSC-CVPCs, (D) human atrium, and (E) ventricle with IF 
markers DAPI (blue), ACTN1 (red), and CX43 (green). (F) Immunofluorescence staining iPSC-
CVPCs with IF markers DAPI (blue), MLC2a+ (red) and MLC2v+ (green), and MLC2v+ 
MLC2a+ (yellow). (G) scRNA-seq UMAP plot showing the presence of three populations: CMs 
(orange), EPDCs (blue) and ESCs (green). (H) scRNA-seq UMAP plot showing the distribution of 
the nine analyzed samples (8 iPSC-CVPC lines and one ESC line) across the three clusters. (I) 
Scatterplot showing the correlation between the %cTnT and the fraction of cells in Population 1 
(CMs) for each of the nine samples. (J) Heatmap showing across all 34,905 single cells the 
expression markers for: 1) stem cells (POU5F1; SOX2; 2) CMs (NKX2-5, ACTN2, TNNT2, 
MEF2C, MYL7, GATA4); 3) EMT (POSTN, SNAI2); 4) fibroblasts (DDR2, THY1); and 5) smooth 
muscle (PDGFRB, TAGLN2, CNN1, ACTA2, VIM, TAGLN).  
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1.3.2 Subset of cells show differential response to WNT inhibition during 
differentiation 
To examine the cellular heterogeneity in the iPSC-CVPCs, we performed single-
cell RNA-seq (scRNA-seq) on eight samples with varying %cTnT values (42.2 to 95.8%) 
and combined these data with scRNA-seq from the H9 ESC line (total of 34,905 cells). 
We detected three distinct cell populations: 1) Population 1, 21,056 cells (60.3%); 2) 
Population 2, 11,044 cells (31.6%); and 3) Population 3, 2,805 cells (8.1%, Figure 1.1g). 
While Populations 1 and 2 were comprised of the eight iPSC-derived samples, Population 
3 almost exclusively included ESC cells (97.7% of the 2,870 ESC cells, Figures 1.1h). 
The relative proportions of cells that each of the iPSC-CVPC samples contributed to 
Population 1 versus Population 2 was strongly correlated with its %cTnT value (r = 
0.938, p = 1.89 x 10-4, t-test; Figure 1.1i), suggesting that Population 1 was 
cardiomyocytes. 
As cardiomyocytes (CMs) and epicardium lineage cells could both survive 
lactate purification 14,15, we investigated if the non-myocyte cells composing Population 2 
were iPSC-epicardium-derived cells (iPSC-EPDCs). We examined the expression levels 
of 17 marker genes (Figure 1.1j) specific for either CMs or EPDCs (including smooth 
muscle, fibroblasts, genes involved in EMT) and two marker genes for stem cells. 
Consistent with having a high number of cTnT-positive cells, Population 1 expressed 
high levels of CM-specific genes, while Population 2 expressed high levels of EPDC-
specific genes, and Population 3 expressed high levels of the stem cell markers POU5F1 
and SOX2 (Figure 1.2a,b). Of note, TNNT2 was expressed in some of the cells in 
Population 2, which is consistent with the strong, but not absolute correlation between 
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%cTnT value and fraction of Population 1 (Figure 1.1i), and previous studies showing 
that some EPDCs express TNNT2 7. These results show that the small molecule 
differentiation protocol followed by lactate purification resulted in the absence of 
undifferentiated cells at D25 and in the derivation of two distinct cell populations, one of 
which expresses high levels of CM markers, including TNNT2, NKX2-5 and MEF2C 
(Population 1), and the other which expresses EPDC markers, including SNAI2, DDR2, 
VIM and ACTA2 (Population 2). Of note, the protocols for generating iPSC-derived 
cardiomyocytes (iPSC-CMs) and iPSC-EPDCs both involve activating the WNT 
signaling pathway 10,15 and have a shared intermediate mesoderm progenitor, but 
subsequent WNT inhibition directs differentiating cells to iPSC-CMs and endogenous 
levels of WNT signaling direct differentiating cells to iPSC-EPDCs 7 (Figure 1.1a). 
Therefore, our results suggest that iPSC-CVPC cellular heterogeneity results from 
suboptimal WNT inhibition in a subset of cells during differentiation, which then give 
rise to EPDCs. 
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Figure 1.2 Distribution of single cells across three clusters 
(a) Distribution of single cells across the three cell populations for the nine analyzed samples: 
scRNA-seq UMAP plots from 34,905 single cells showing their distributions across the three 
different clusters for the nine analyzed samples (8 iPSC-CVPCs lines and one ESC line). Each of 
the nine samples has a different color, as indicated in Figure 1.1i. (b) Expression levels for marker 
genes: For each gene in Figure 1.1j, density plots show the gene expression distribution across all 
cells associated with each cell population (Population 1 = orange; Population 2 = blue; Population 
3 = green.). Red dashed line represents the median. UMAP plots from 34,905 cells show in 
maroon all the cells expressing the indicated marker gene higher than its median expression across 
the three populations. 
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1.3.3 iPSC-CVPCs are composed of immature CMs and EPDCs  
 
To estimate the relative abundances of CM and EPDC cells across our collection 
of iPSC-CVPC samples, we selected the top 50 significantly overexpressed genes in each 
of the three scRNA-seq populations (150 genes in total, p < 10-13, edgeR), obtained their 
expression levels in bulk RNA-seq from 180 iPSC-CVPCs, and inputted these values into 
CIBERSORT 16. We observed that the proportions of each cell type varied across the 
samples, although the iPSC-CVPCs tended to have a greater fraction of CMs (84.8 ± 
31.8%, Figure 1.3a) than EPDCs (14.7 ± 32.0%), and essentially no stem cells (0 ± 
0.8%). Due to lactate selection, the small number (67) of cells predicted to be ESCs may 
represent a distinct differentiated cell type that is more similar to stem cells than either 
CMs or EPDCs. The estimated fraction of CMs and EPDCs in the iPSC-CVPCs was 
highly correlated with %cTnT values (r = 0.927, p  0; t-test Figure 1.3b), similar to that 
observed in the analysis of the scRNA-seq data (Figure 1.1j). Finally, we showed that the 
iPSC-CVPCs with high estimated CM or EPDC cellular fractions respectively showed 
higher expression of CM markers (MEF2C, NKX2-5 and ACTN2) and EPDC markers 
(ACTA2, TAGLN, DDR2 and SNAI2, Figure 1.3c). These results indicate that cellular 
heterogeneity across iPSC-CVPC samples largely reflects different proportions of CMs 
and EPDCs. 
To characterize the similarities between the iPSC-CVPC transcriptomes and 
those of adult heart and artery samples, we performed a PCA analysis using the 
transcriptomes of 184 iPSCORE iPSCs, 180 iPSC-CVPCs, and the 1,072 GTEx samples, 
including left ventricle, atrial appendage, coronary artery and aorta 17.We found that 
principal component 1 (PC1) showed that iPSC-CVPCs correspond to an intermediate 
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state between the iPSCs and adult samples, suggesting that the derived CMs and EPDCs 
are similar to immature cardiac cells (Figure 1.3d). PC2 divided the samples based on 
cardiac lineage, namely the myocardium (left ventricles and atrial appendages) and 
epicardium (coronaries and aorta) 18. This analysis shows that derived iPSC-CMs and 
iPSC-EPDCs lie on different cardiac developmental trajectories, with the CMs 
corresponding to immature myocardium and the EPDCs to immature epicardium.  
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Figure 1.3 Transcriptomic features of 180 iPSC-CVPC samples 
(a) Relative distributions of cell populations estimated using CIBERSORT across 180 iPSC-
CVPC samples. (b) Scatterplot showing the correlation between %cTnT (X-axis) and the fraction 
of Population 1 in the iPSC-CVPCs calculated using CIBERSORT (Y-axis). (c) Heatmap showing 
the expression levels of CM and EPDC marker genes (Figure 1.1j) in 180 iPSC-CVPC samples at 
D25. Samples are colored based on their fraction of Population 1. (d) PCA on the 1,000 genes 
with highest variability from 184 iPSC samples, 180 iPSC-CVPC samples (triangles colored 
according to their % Population 1), and samples from GTEx (squares, left ventricle, right 
ventricles, coronary artery and aorta).  
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1.3.4 iPSC expression signatures impact cardiac fate differentiation 
 
Although all iPSCORE iPSCs have previously been shown to be pluripotent 19, 
we sought to determine if transcriptomic differences existed between the iPSC lines that 
derived CVPCs containing CMs versus those that gave rise to EPDCs (Figure 1.4a). 
Given that all 180 iPSC-CVPCs contain both CMs and EPDCs but at different ratios, we 
initially had to determine the optimal CM:EPDC ratio to group the iPSC lines into those 
that were CM-fated and those that were EPDC-fated. Thresholds for 193 iPSC-CVPCs 
that completed differentiation (harvested on D25) were defined by the ratio of CM:EPDC 
estimates from CIBERSORT (estimated %CM: estimated %EPDC), while the 39 iPSC-
CVPC differentiations terminated prior to D25 for not forming a beating syncytium were 
assigned a CM:EPDC ratio of 0:100 (0% CM:100% EPDC). We tested ten different 
CM:EPDC ratios and found 116 autosomal genes that were differentially expressed at 
one or more of these ratios (Storey q-value < 0.1, t-test, Figure 1.4a,b). We observed that 
the maximum number of the 116 genes (84, 72.5%) were differentially expressed at the 
30:70 (CM:EPDC) threshold and 55 of them (47.4%) had their strongest p-value at this 
ratio. For this reason, we determined that the 30:70 threshold was optimal and grouped 
the iPSCs into 125 that were CM-fated (produced ≥ 30% CMs), and 59 that were EPDC-
fated (produced >70% EPDCs, Figure 1.4b).  
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Figure 1.4 iPSC gene signatures associated with cardiac differentiation fate 
(a) Testing of ten CM:EPDC ratios (0:100 to 90:10, with 10% increments) to determine the 
optimal threshold for defining an iPSC as CM-fated or EPDC-fated. For each threshold the 
number of iPSC lines defined as CM-fated (orange) or EPDC-fated (blue) is shown. (B) At the 
same thresholds indicated in (A), shown are the numbers of differentially expressed autosomal 
genes between the iPSC lines defined as CM-fated and EPDC-fated. The 30:70 threshold has the 
maximum number of differentially expressed genes. (C) Volcano plot showing mean difference in 
expression levels for all autosomal genes between CM-fated iPSC lines (their corresponding 
derived samples have CM population > 30%) and EPDC-fated iPSC lines (X axis) and p-value (Y 
axis, t-test). A positive difference indicates over-expression in CM-fated iPSCs, whereas a 
negative difference indicates over-expression in EPDC-fated iPSCs. Significant genes are 
indicated in red. (D) Expression levels of the 91 signature genes in iPSCs as a function of the % 
CM population in their corresponding iPSC-CVPC samples. Thick lines represent the average for 
36 genes overexpressed in CM-fated iPSCs (orange) and for 55 genes overexpressed in EPDC-
fated iPSCs (blue). (E) WNT/ß-catenin pathway, muscle/cardiac related, or EMT/mesenchymal 
development signature genes (those differentially expressed with nominal p-values (p < 0.0015) 
indicated with an asterisk). (F) GLM estimate (% CM population ~ expression) calculated for each 
signature gene. Mean and 95% confidence interval are shown. (G) Bar plot showing the 
percentage of variability in iPSC fate that is explained by each of the 91 signature genes. Bars 
highlighted in red show the 35 signature genes identified by L1 normalization that independently 
contributed to variance. Due to the fact that the 91 genes do not have independent expression, the 
total sum of the % variance explained is >1. 
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Of the 84 autosomal differentially expressed genes at the 30:70 (CM:EPDC) 
threshold, 35 were overexpressed in the CM-fated iPSC lines and 49 were overexpressed 
in the EPDC-fated iPSCs (Figure 1.4b,c,d). These genes have functions associated with 
three differentiation signatures: 1) Wnt/β-catenin pathway (13 genes); 2) muscle and/or 
cardiac differentiation (six genes); and 3), EMT and/or mesenchymal tissue development 
(six genes, Figure 1.4e). We noted that seven borderline significant autosomal genes were 
also involved in one of the three represented signatures, and therefore added them to the 
final list of differentially expressed genes. We investigated the associations between the 
expression levels of the final list of 91 signature genes (Table 1.2) in the 184 iPSCs and 
the fraction of CMs in the resulting iPSC-CVPCs using linear regression, and found 
significant associations for all genes (Figure 1.4f). These results show that, independently 
from the 30:70 (CM:EPDC) threshold used in the initial differential expression analysis, 
the expression levels of these signature genes in the 184 iPSCs were significantly 
associated with differentiation outcome (e.g. CM- or EPDC-fate). 
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Table 1.2 All 91 genes significantly differentially expressed 
between CM-fated and EPDC-fated iPSCs  
Gene Name Expression Difference p-value (t-test) Storey q-value 
PRCC 0.618529454 2.88E-06 0.01205865 
FOS 0.558406525 6.67E-06 0.013943832 
WRNIP1 0.513679615 5.87E-06 0.013943832 
CDK13 0.463221631 0.000112617 0.034464603 
CTNNBL1 0.462866405 4.51E-05 0.02910997 
TSHZ3 0.461497119 0.000286561 0.06420694 
SMARCE1 0.459118456 0.000110539 0.034464603 
RANBP9 0.458788345 3.33E-05 0.024611753 
TAF12 0.449478357 2.40E-06 0.01205865 
DDX27 0.448880833 3.69E-05 0.025726776 
GSK3A 0.444607137 5.14E-05 0.02910997 
LRRC47 0.438821079 5.45E-05 0.02910997 
FAM32A 0.434495706 8.62E-05 0.031155239 
EIF6 0.429786878 2.59E-05 0.024611753 
KLF10 0.414685251 0.000616654 0.092558302 
LENG1 0.408202719 0.000713826 0.09735479 
MCM6 0.401969502 0.000227921 0.054996333 
RNF31 0.401277066 0.00073254 0.098832907 
FAF2 0.383104624 0.000473391 0.083467392 
SMAP2 0.376384072 0.000253781 0.060080777 
MED10 0.370823102 0.000102522 0.033852295 
HSPH1 0.369954886 0.000175825 0.044122921 
OTUB1 0.365142144 0.000641798 0.09281717 
FKBP15 0.357407066 0.000555377 0.091691214 
GNAI2 0.354845566 0.000334199 0.071073176 
PIP5K1A 0.334889726 0.000713791 0.09735479 
RAB5B 0.328344869 0.000383614 0.071841008 
GPR176 0.321026033 0.000347509 0.071262367 
POLR3A 0.316185628 5.36E-05 0.02910997 
NCKIPSD 0.30889223 0.000650965 0.09281717 
ZNF407 0.306692831 0.000368762 0.071816322 
UBN2 0.296411412 0.000394992 0.072205659 
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Table 1.3 All 91 genes significantly differentially expressed 
between CM-fated and EPDC-fated iPSCs (Continued) 
Gene Name Expression Difference p-value (t-test) Storey q-value 
TTI1 0.294890987 0.000619643 0.092558302 
PLRG1 0.294560965 0.000432973 0.077609668 
SNRNP200 0.290958385 5.93E-05 0.02910997 
CSDE1 0.282710822 0.00089626 0.105070434 
LMAN1 -0.202369391 0.000339866 0.071073779 
STT3B -0.234785987 0.000478957 0.083467392 
SYTL1 -0.242179725 0.000593076 0.092004325 
CALU -0.253299668 2.30E-05 0.024413109 
FSTL3 -0.271361948 0.000260981 0.060641254 
TMEM259 -0.276598907 0.000120441 0.035144568 
RABL6 -0.278855606 0.000499478 0.085851237 
TLE3 -0.290777299 0.001171725 0.113969644 
EXTL2 -0.306679543 1.49E-05 0.020835271 
FBXO5 -0.308185476 5.95E-05 0.02910997 
B4GALNT4 -0.30848578 0.000129442 0.036912736 
PIDD -0.309094532 0.000381197 0.071841008 
ALDH1B1 -0.317848552 0.001106848 0.112000298 
RPS15 -0.318386014 0.000671838 0.093784302 
APOE -0.319862507 2.33E-05 0.024413109 
SCN4B -0.327868094 0.000880088 0.105070434 
CLDN3 -0.3318153 0.000834927 0.105070434 
ATP5F1 -0.332244288 9.55E-05 0.033278093 
WFS1 -0.33560547 0.000517693 0.087779657 
FGD5-AS1 -0.340267921 0.000541854 0.090651242 
RHPN1 -0.344623087 6.54E-05 0.029583781 
PTPLAD1 -0.353806396 3.07E-05 0.024611753 
YES1 -0.356807254 8.46E-06 0.015164087 
BTBD17 -0.361029531 0.000147429 0.039358532 
DDX11 -0.363962468 0.000630168 0.09281717 
FBXL15 -0.364558194 0.000601269 0.092004325 
IKBIP -0.365221839 0.000100393 0.033852295 
RTN4R -0.36702925 0.000272395 0.062142609 
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Table 1.4 All 91 genes significantly differentially expressed 
between CM-fated and EPDC-fated iPSCs (Continued) 
Gene Name Expression Difference p-value (t-test) Storey q-value 
CD4 -0.377453722 0.00039707 0.072205659 
RP11-486G15.2 -0.377453777 0.00036343 0.071816322 
B3GNT1 -0.380958591 0.000672697 0.093784302 
ZNF219 -0.383156897 0.000372035 0.071816322 
MGAT1 -0.386426098 0.000141543 0.038608449 
FAM35A -0.390447022 8.25E-07 0.010347182 
ENPP5 -0.393241942 0.000333879 0.071073176 
CMBL -0.405426981 0.000352127 0.071262367 
F2R -0.407691113 7.54E-05 0.029583781 
CCBE1 -0.408620523 0.001349212 0.115952539 
LRFN4 -0.417677335 3.27E-05 0.024611753 
MICALL2 -0.420069961 6.03E-05 0.02910997 
WFIKKN1 -0.426110939 0.000112023 0.034464603 
C18orf56 -0.426783944 7.85E-05 0.029840058 
ZNF670 -0.432012917 2.76E-05 0.024611753 
GDF1 -0.432533942 5.03E-06 0.013943832 
C19orf60 -0.434593453 0.00019482 0.047931036 
PURG -0.436080216 0.000643584 0.09281717 
LRFN1 -0.440493195 0.000135821 0.037871174 
CYB5R1 -0.44313245 0.000600015 0.092004325 
C11orf31 -0.443214265 7.12E-05 0.029583781 
RP3-449O17.1 -0.452125413 2.22E-05 0.024413109 
TGFBI -0.452163339 0.001308647 0.114534817 
AC024560.3 -0.468757978 0.000585005 0.092004325 
NPTX2 -0.492895354 7.37E-05 0.029583781 
COL8A2 -0.498153533 6.88E-05 0.029583781 
CD82 -0.527262952 1.09E-05 0.017147403 
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1.3.5 Signature genes capture a large fraction of the variance underlying iPSC fate 
outcome  
While the signature genes likely impacted cardiac fate determination, we did not 
expect each gene to contribute equally. To explore the impact of each gene individually 
on differentiation outcome, we calculated how much the 91 genes explained the 
variability underlying iPSC cell fate. To quantify the percent of variance explained by 
each gene (R2), we fit a generalized linear regression model with a logit link function to 
each gene individually. We found that the percent of variance explained by each 
individual gene varied over three orders of magnitude (1.73 x 10-3<R2< 8.97%; Figure 
1.4g). 
We next asked how these signature genes altogether captured variability in 
differentiation fate. As several of the signature genes had correlated expression levels, to 
reduce overfitting in the regression analysis, we included an L1 norm penalty (i.e. 
LASSO regression) and used 10-fold cross validation. We identified 35 genes that 
independently contributed to variance, and whose expression levels collectively 
explained more than half of the variability in differentiation outcome across iPSC lines 
(average R2 from the 10-fold cross validation = 0.512). Together these data show that, 
while the proportion of variance explained by each of the signature genes varied widely, 
altogether they captured approximately half of the total variance underlying differential 
iPSC fate outcome. 
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1.3.6 Inherited genetic variation does not influence differentiation outcome 
 
We investigated if genetic variation associated with the expression of any of the 
signature genes contributed to the differentiation outcome of iPSCs. We assessed the 
genotypes of 8,620,159 variants in each iPSC line and performed a GWAS study to 
investigate the association between genotype and the fraction of CMs in the 
corresponding iPSC-CVPCs. We found that none of these variants associated with 
differentiation outcome at genome-wide significance (p < 5 x 10-8, Figure 1.5a). To 
further examine the association between genetic background and differentiation outcome, 
we tested if differentiations of different iPSC clones from the same individual, and from 
members of the same twin pair, were more likely to yield similar outcomes compared 
with differentiations of iPSC clones from individuals with different genetic backgrounds, 
and observed similar distributions Figure 1.5b). While our power to perform a GWAS 
study was limited, this analysis shows that the genetic background did not contribute to 
the variance underlying iPSC differentiation outcome, indicating that non-genetic (i.e., 
clonality and passage) factors played a role in determining whether an iPSC line 
differentiated to CMs or EPDCs. 
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Figure 1.5 Associations between genetic background and differentiation outcome 
(a) Manhattan plot showing the association between genetic variation and differentiation outcome 
(measured as % CM population in iPSC-CVPCs). Red dashed line shows p-value = 0.05 adjusted 
using Bonferroni’s method (p = 5 x 10-8). (b) Boxplots showing distributions of the differences in 
the %CM population between differentiations of different iPSC clones from the same subject, 
from the same twin pair, and from individuals with different genetic backgrounds. P-values were 
calculated using Mann-Whitney U test. 
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1.3.7 GSEA implicates ELK1 targets and genes on the X chromosome  
 
To understand whether the transcriptomic differences between CM-fated and 
EPDC-fated iPSCs were associated with alterations in specific pathways or cellular 
function, we performed a gene set enrichment analysis (GSEA) on 9,808 MSigDB gene 
sets 20 using the 15,228 expressed autosomal genes in the 184 iPSCs. We identified 22 
gene sets that were significantly associated with iPSC cell fate, including enrichment in 
the 59 EPDC-fated iPSCs for extracellular matrix (Figure 1.6a) and in the 125 CM-fated 
iPSCs for transcription factor activity and ELK1 targets. To capture gene sets associated 
with expression differences on the X chromosome, we performed differential expression 
and GSEA on 113 female iPSC lines (87 CM-fated; 26 EPDC-fated). The two most 
significant gene sets were loci located within chrXp11 and chrXp22 (Figure 1.6b). 
Notably, the chrXp11 locus encodes both ELK1 and PORCN, whose protein product 
(Porcupine) is targeted for WNT inhibition in CM differentiation protocols, but not 
EPDC differentiation protocols 8,9 (Figure 1.6b). The chrXp22 locus includes the majority 
of genes (52/99, 52.5%) that are known to escape chromosome X inactivation 21, and thus 
may potentially have varying X-linked gene dosage across female iPSCs. Overall, GSEA 
shows that genes differentially expressed between CM-fated and EPDC-fate iPSCs are 
involved in a variety of pathways including ELK targets and potentially associated with 
the X chromosome activation status. 
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Figure 1.6 X chromosome gene dosage plays a role in cardiac differentiation fate 
(a) GSEA results: For each gene set, -log10(q-value) is shown. Positive values correspond to gene 
sets enriched in CM-fated iPSCs, whereas negative values correspond to EPDC-fated iPSCs. For 
autosomes all iPSCs were included (top), for the chromosome X only the 113 female iPSCs were 
analyzed (bottom). Storey q-value was used to adjust for multiple testing hypothesis, q-values < 
0.05 were considered significant. (B) Cartoon showing the differentially expressed loci on 
chromosome X and the position of ELK1 and PORCN. (C) Barplot showing the associations 
between sex and differentiation outcome (orange: iPSC-CVPC samples with CM fraction > 30%; 
blue: with EPDC fraction > 70%). P-values were calculated using Z-test (glm function in R). (D) 
Density plot showing the differences in allelic imbalance fraction between autosomal genes (pink) 
and chrX genes outside of the pseudoautosomal region (maroon) in female iPSCs. (E) Density plot 
showing the differences in allelic imbalance fraction between chrX genes in female CM-fated 
(light orange) and EPDC-fated (light blue) iPSCs. (F) Density plot showing the differences in 
allelic imbalance fraction between chrX genes in female D25 iPSC-CVPC samples with CM 
fraction > 30% (orange) and EPDC fraction > 70% (blue). P-values in D-F were calculated using 
Mann Whitney U test. 
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1.3.8 Sex is associated with iPSC differentiation outcome 
 
To identify other iPSC factors potentially associated with differentiation 
outcome, we examined three characteristics of the 181 subjects in our study (sex, 
ethnicity, and age) and passage of the iPSCs at D0. Analyzing the 125 CM-fated and 59 
EPDC-fated iPSC lines with a general linear model, we found no association between 
differentiation outcome and ethnicity or age (p > 0.8; GLM, Z-test; Figure 1.7a,b), but 
observed a significant association with sex (p = 2.57x10-5, GLM, Z-test; Figure 1.6c) and 
a trend for iPSC passage at D0 (p = 0.069, GLM, Z-test; Figure 1.7c). These data suggest 
that iPSCs derived from female subjects and iPSCs with higher passages at D0 had an 
increased predisposition for the CM fate. Furthermore, considering only the 191 
completed differentiations (D25 iPSC-CVPC samples), we found that iPSC-CVPC 
samples derived from female subjects compared to those derived from males had 
significantly higher %cTnT values (mean = 83.0% and 77.7%, respectively for females 
and males, p = 6.0 x 10-4, Mann-Whitney U test; Figure 1.7d) and a higher fraction of 
CMs (p = 6.46 x 10-4, Mann-Whitney U test; Figure 1.7e). These results indicate that 
iPSCs derived from female subjects and, to a lesser extent, iPSCs that have spent more 
time in cell culture, have a greater inherent predisposition to differentiate towards the CM 
lineage. 
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Figure 1.7 X chromosome inactivation in iPSCs 
(a,b,c) Associations between differentiation outcome (orange: iPSC-CVPC samples with CM 
fraction > 30%; blue: with EPDC fraction > 70%) and (a) ethnicity (most similar superpopulation 
from the 1000 Genomes Project), (b) age at enrollment, and (c) passage at monolayer (D0). (a) is 
shown as barplots; (b,c) are shown as density plots. P-values were calculated using Z-test (glm 
function in R). (d,e) Density plots showing the association between sex (teal: males; magenta: 
females) and (d) %cTnT, and (e) fraction of CM population for 191 iPSC lines. P-values were 
calculated using Mann-Whitney U test. (f) Allelic imbalance difference between CM-fated and 
EPDC-fated iPSCs. The dots represent each gene on chrX, while the black solid line corresponds 
to the smoothed interpolation of differences for all the genes. The locations of the Xp22 and Xp11 
loci on the chrX G-banding ideogram are highlighted in yellow, as well as ELK1 (yellow) and 
PORCN (red). P-values above each locus indicate the difference in allelic imbalance between CM-
fated and EPDC-fated iPSCs in each locus (Mann Whitney U test). (g,h,i) Allelic imbalance 
fraction from inactive and escape genes in Xp22: Density plots showing the allelic imbalance 
differences in chrX genes on the Xp22 loci in female samples between iPSC lines with CM-fate 
(light blue) and EPDC-fate (light orange) differentiations. Allelic balances compared in Xp22 are 
from all genes in the region (g), escape genes (h), and inactive genes (i). P-values were calculated 
using Mann Whitney U test. 
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1.3.9 Female iPSCs with X chromosome reactivation associated with CM fate  
 
Given the observation that female iPSCs have a greater potential to differentiate 
to CMs and that differential expression of chrXp11 genes were associated with 
differentiation outcome, we asked if variation in X chromosome inactivation (Xi) and 
activation (Xa) state across female iPSC lines was associated with CM or EPDC-fate. 
Using RNA-seq data generated from the 113 female iPSCs, we evaluated allele specific 
effects (ASE) of X chromosome and autosomal genes. We defined the strength of ASE 
for each gene as the fraction of RNA transcripts that were estimated to originate from the 
allele with higher expression (hereto referred to as “allelic imbalance fraction”, AIF). We 
observed that AIF in autosomal genes was close to 0.5, indicating that both alleles were 
equally expressed (Figure 1.6d), while AIF on the X chromosome in iPSCs tended to be 
bimodal, with some genes showing monoallelic expression (AIF ~1.0; XaXi) and others 
showing biallelic expression (AIF ~0.5; XaXa). We observed that AIF was less in the 87 
CM-fated female iPSCs compared with the 26 EPDC-fated female iPSCs (p = 0.011, 
Mann-Whitney U test, Figure 1.6e) and that this difference in AIF became even more 
pronounced in the corresponding derived iPSC-CVPC samples (p = 4.81x10-6, Mann-
Whitney U test, Figures 1.6f, 1.7f). These finding show that differential chromosome 
XaXi status, as well as altered gene expression in chrXp22 and chrXp11, in iPSCs 
contribute to differences in cardiac fate differentiation outcome. 
Since we observed differences in X chromosome reactivation state between CM-
fated and EPDC-fated female iPSCs, we next asked if the two GSEA X chromosome 
associated intervals (chrXp22 and chrXp11; Figure 1.6a) showed corresponding allelic 
imbalance trends. We plotted AIF differences, where a positive AIF difference indicates 
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X chromosome reactivation in the 26 EPDC-fated iPSCs and a negative in the 87 CM 
fated-iPSCs (Figure 1.7f). We observed that distinct regions across the X chromosome 
were differentially eroded in the EPDC-fated versus CM-fated iPSCs. In particular, 
chrXp22 showed X reactivation in CM-fated iPSCs (p = 6.31 x 10-3, Mann Whitney U), 
with both escape (p = 0.020, Mann Whitney U) and non-escape genes (p = 0.023, Mann 
Whitney U) showing evidence of reactivation (Figure 1.7g,h,i). As chrXp22 contains 
more than half of escape genes on the X chromosome, this observation confirms that 
increased X reactivation in CM-fated iPSCs results in increased expression of both 
escape and non-escape genes. As GSEA identified genes on chrXp11 to be overexpressed 
in CM-fated iPSCs, the lack of X reactivation in this interval (p = 0.28, Mann Whitney 
U) suggests alternative regulatory mechanisms may also alter gene expression levels on 
the X chromosome. Overall, these results suggest that differential X chromosome 
reactivation as well as other mechanisms underlying altered regulation of X chromosome 
and autosomal genes contribute to iPSC cardiac lineage fate determination 
 
1.3.10 Independent iPSC-CM derivation study validates findings 
 
To assess the generalizability of our findings, we examined an independent 
collection of 39 iPSCs 12 reprogrammed using an episomal plasmid from Yoruba 
lymphoblastoid cell lines Figure 1.8a). Differentiation of these lines resulted in the 
successful derivation of 13 iPSC-CMs (%cTnT range at D32: 40 to 96.9), whereas 24 
were terminated on or before day 10 due to the fact that they did not form a beating 
syncytium. To examine if the successfully derived Yoruba iPSC-CMs showed the 
presence of EPDCs, we used RNA-seq data and CIBERSORT to estimate cellular 
  
 
30 
 
compositions and observed variable relative distributions of CM and EPDC populations 
(Figure 1.8b). Consistent with our iPSCORE iPSC-CVPC samples, the estimated CM 
population fractions were significantly correlated with %cTnT values (r = 0.81, p= 7.94 x 
10-4, t-test; Figure 1.8c). To understand if the CMs and EPDCs appear at the same time 
during differentiation, we analyzed data generated the from the Yoruba lines a four 
timepoints 22 and observed that both cardiac lineages are typically present by day 5 and 
that the ratio of these two cardiac cell types remains relatively stable past day 10. Finally, 
Yoruba iPSC-CMs derived from females tended to have an increased percentage of CMs 
compared with those derived from males (Figure 1.8d). These observations show that the 
Yoruba iPSCs and derived cardiac cells could be used to investigate the generalizability 
of the associations that we had observed between transcriptomic differences in iPSCs and 
cardiac fate differentiation outcome. 
As several factors (Figure 1.8a) were different between the iPSCORE iPSC and 
Yoruba iPSC sets (i.e. different reprogramming method, genetic backgrounds, and donor 
cell types), we expected that there would be significant differences between their 
transcriptional profiles. We initially analyzed how correlated gene expression was: 1) 
within iPSCORE iPSCs; 2) within Yoruba iPSCs; and 3) between all pairwise 
comparisons of the iPSCs in these two different collections (Figure 1.8e). We observed 
high correlations of gene expression across iPSCs within each collection, however the 
correlation between samples from different studies was significantly decreased, 
indicating that the two sets have significant genome-wide gene expression differences. 
We next examined differential gene expression between the CM-fated iPSCORE iPSC 
and Yoruba iPSCs that successfully differentiated into iPSC-CMs (Figure 1.8f), and 
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observed that the majority of genes (69.6% with q-value < .10) were significantly 
differentially expressed between the two iPSC sets. These results show that there are 
strong batch effects on gene expression between the iPSCORE and Yoruba iPSC lines. 
  
  
 
32 
 
Figure 1.8 Validation of association between iPSC gene signatures, sex and differentiation 
outcome 
(a) Schematic depicting differences (subject ethnicities, donor cell type, reprogramming method) 
between the iPSCORE iPSC and Yoruba iPSC as well as differences in the cardiac differentiation 
protocol. (b) Estimated fractions of CMs and EPDCs for 13 Yoruba iPSC-CM samples from 
RNA-seq using CIBERSORT (two iPSC-CMs did not have RNA-seq). (c) Scatterplot showing the 
correlation between %cTnT (X axis) and the fraction of cells in population 1 (% CMs) calculated 
using CIBERSORT (Y axis) for 13 Yoruba iPSC-CM samples. (d) Boxplots showing the 
distribution of estimated fraction of cells in population 1 (% CMs) for 9 female Yoruba iPSC-CM 
and 4 male Yoruba iPSC-CM. P-value was calculated using Mann-Whitney U test. (e) Box plots 
showing correlation of gene expression in all 184 iPSCORE iPSCs with RNA-seq (purple), 34 
Yoruba iPSCs with RNA-seq used for differentiation (yellow; 14 successful iPSC and 20 
terminated iPSC, five iPSCs did not have RNA-seq), and the pairwise comparison of the Yoruba 
iPSC against the iPSCORE iPSC (grey). (f) Volcano plot showing mean difference in expression 
levels for all autosomal genes between 14 Yoruba iPSC lines that were successfully differentiated 
and 125 iPSCORE iPSC lines that differentiated to >30% Population 1 (CMs) (X-axis) and p-
value (Y-axis, t-test). A positive difference between mean expressions indicate iPSCORE-specific 
over-expression, whereas a negative difference between mean expressions indicate Yoruba-
specific over-expression. Significant genes are indicated in red. (g) Smooth color density 
scatterplot showing gene expression differences between iPSCs with different fates in 184 
iPSCORE iPSC (125 CM-fated vs 59 EPDC-fated) (X-axis) to the expression differences between 
iPSCs with different outcomes in Yoruba iPSC (14 successful vs 20 terminated) (Y-axis). A 
positive difference indicates shared over-expression of genes between CM-fated iPSC in 
iPSCORE and successfully differentiated iPSC in the Yoruba set, whereas a negative difference 
indicates shared over-expression of genes between EPDC-fated iPSC in iPSCORE and terminated 
iPSC in the Yoruba set. Of the 91 signature genes that were differentially expressed in the 
iPSCORE iPSCs based on cell fate, eight had nominally significant expression differences in the 
same direction in the Yoruba iPSC set (shown in red). (h) Barplot showing that the eight 
iPSCORE differentially expressed genes (panel g) with nominal significant expression differences 
in the same direction (e.g. over-expressed or down regulated) in the Yoruba iPSCs is greater than 
random expectation. Of 13,704 genes expressed both in the iPSCORE and Yoruba iPSCs, we 
obtained 6,909 for which the average normalized expression differences had either the same 
positive (CM fate/successful differentiation) or negative (EPDC fate/terminated differentiation) 
direction. The 6,909 genes included 47 of the 91 iPSCORE signature genes. We found that 466 
(6.7%) of the 6,909 genes were nominally significant for being differentially expressed between 
the 14 successful and 20 terminated differentiations in the Yoruba samples, while 8 of the 47 
iPSCORE differentially expressed genes (17.0%) had a nominal p < 0.05. This analysis shows that 
the 91 iPSCORE signature genes are 2.5 times more likely than expected (17.0% vs. 6.7%, p = 
0.012, Fisher’s exact test) to be differentially expressed in the Yoruba samples based on cardiac 
differentiation fate.  
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We investigated if, despite the strong batch effects on gene expression between 
iPSCORE and Yoruba iPSCs, we could detect inherent transcriptional differences 
impacting cardiac fate determination that were shared between the iPSC sets. Given the 
relatively small size of the Yoruba study there was insufficient power to detect 
transcriptional differences between the lines with different differentiation outcomes 
(Successfully completed versus Terminated). Therefore, for each gene, we compared the 
mean expression differences between iPSCs with different cardiac fate outcomes in 
iPSCORE (CM-fate – EPDC-fate) to the expression differences between iPSCs with 
different differentiation outcomes in the Yoruba set (Successfully completed – 
Terminated, Figure 1.8g). We observed a small, but significant correlation (r = 0.0299, p 
= 4.71 x 10-4, t-test) between genes that were differentially expressed in the iPSCORE 
iPSCs and those that were differentially expressed in the Yoruba iPSCs. Further, we 
specifically examined the 91 signature genes significantly associated with iPSCORE 
iPSC cardiac fate outcome and found eight with nominally significant expression 
differences in the same direction (e.g. overexpressed or downregulated) in the two sets of 
iPSCs (Figure 1.8g), which is 2.5 times more than random expectation (p = 0.012, 
Fisher’s exact test; Figure 1.8h). These data suggest that the iPSCORE iPSCs and Yoruba 
iPSCs shared transcriptional differences that impacted cardiac fate differentiation 
outcome. 
 
1.4 Discussion 
 
While previous directed cardiac differentiation studies have observed the 
emergence of both cardiomyocytes and a non-contractile cell population, the origin of 
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these non-contractile cells, and whether the same or different non-myocyte cell types are 
present across iPSC-CVPC samples has not previously been addressed. We showed that 
two distinct cell types were present in 154 iPSC-CVPC samples derived from iPSCs in 
iPSCORE. One of the derived cell types were cardiomyocytes (CMs), characterized by 
high expression levels of cardiac-specific genes, and the other derived cell type was 
epicardium-derived cells (EPDCs), characterized by high expression of marker genes for 
EMT, smooth muscle and fibroblasts. We found the same two cardiac cell types present 
in iPSC-CMs derived from an independent collection of 39 Yoruba iPSCs; and that both 
cardiac cell types were typically present by day 5 and their ratios remained relatively 
stable past day 10 12,22. A recent study showed that adding hESC-derived epicardial cells 
to cardiomyocyte grafts in vivo improves transplantation efficacy, as it increases 
contractility, myofibril structure and calcium handling and decreases tissue stiffness 23. 
Our findings suggest that the generation of EPDCs during iPSC-CM differentiation may 
enhance the structure of the derived CMs; and that to efficiently use iPSC-CVPCs in a 
clinical setting, future studies may need to optimize the relative proportions of CMs and 
EPDCs that maximize their transplantation efficiency. 
The scale of our study, 232 attempted differentiations of 191 iPSC lines into the 
cardiac lineage, provided the power to develop a framework to identify non-genetic 
transcriptional differences in iPSCs that influence their cardiac differentiation outcome. 
To minimize the factors that might influence differentiation outcome, such as the optimal 
cell confluency at which to start differentiation, we attempted to standardize all steps in 
the differentiation protocol, in order to remove subjective decisions and diminish 
experimental differences between samples. We identified 91 signature genes whose 
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differential expression was associated with differentiation outcome and showed that 
many of these genes are involved in cardiac development, including the Wnt/β-catenin 
pathway, muscle differentiation or cardiac-related functions, and the transition of 
epicardial cells to EPDCs by EMT (Figure 1.9). Many of the transcriptomic differences 
between iPSCORE iPSCs with CM-fates versus those with EPDC-fates may be due to 
aberrant epigenetic landscapes resulting from a combination of the reprogramming 
method (Sendai virus) and cell of origin (fibroblasts). However, given that the Yoruba 
iPSCs were reprogrammed using a different method (Episomal plasmid) and cell of 
origin (LCLs), and yet the iPSCORE and Yoruba iPSCs shared gene expression 
differences associated with cardiac lineage outcome, it is likely that our findings will 
likely be generalizable to other collections of iPSCs. We hypothesize that the signature 
genes associated with cardiac lineage outcome will vary across iPSC collections and 
depend on the reprogramming method and cell type of origin but will largely be involved 
in the same pathways identified in this study. 
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Figure 1.9 iPSC characteristics that influence their cardiac fate determination 
(a) Cartoon showing iPSC characteristics that influence their cardiac fate determination, including: 
1) the expression levels of 91 genes grouped into three gene signature classes (WNT/B-catenin 
pathway, cardiac development genes and genes involved in EMT, see Figure 1.4); 2) sex, female 
iPSCs are more likely to differentiate to CMs than males (see Figure 1.6); and 3) X chromosome 
activation state, female iPSCs that have activated both X chromosomes (XaXa) are more likely to 
differentiate to CMs (see Figure 1.6). 
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We observed that variability across iPSCs on X chromosome gene dosage (XaXa 
vs XaXi vs XY) played a role in cardiac lineage fate (Figure 1.6). While human iPSCs 
are known to have only partial XaXa 24,25, we identified two loci (chrXp11 and chrXp22) 
encoding genes whose expression levels are associated with two the distinct cardiac 
differentiation trajectories (CMs vs. EPDCs). The higher expression of chrXp11 genes in 
CM-fated iPSCs may at least in part be due to fact that ELK1 and PORCN are both 
encoded in this interval, as the protein product of PORCN (Porcupine) is inhibited by 
IWP-2 during CM differentiation 8, but not during EPDC differentiation 7,10,11,15 (some 
EPDC protocols inhibit Porcupine but then reactivate the WNT pathway at a later time 
point 26-28. Furthermore, we found that ELK1 targets are overexpressed in CM-fated 
iPSCs, which is consistent with previous studies showing that knockdown of ELK1 in 
immortalized human bronchial epithelial cells, small airway epithelial cells, and luminal 
breast cancer cell line (MCF-7) is associated with increased EMT 29,30. Also consistent 
with ELK1 playing a role in the association between X chromosome dosage and 
differentiation outcome is a previous study showing that ELK1 overexpression or 
downregulation respectively mimics the phenotypes of XaXa or XaXi pluripotent stem 
cells 31. Of note, atrioventricular septal defects (AVSD) occur in ~20% of individuals 
with Down Syndrome (DS), and has a higher prevalence in female DS patients 32. Given 
that EPDCs play an essential role in septal formation 33, our study suggests that future 
work should investigate the extent to which X chromosome gene expression levels are 
altered in cardiomyocytes from individuals with DS, and if this is associated with the 
formation of fewer EPDCs.  
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Overall, our study suggests that expression differences of 91 signature and X 
chromosome genes result in the iPSCORE iPSC lines having differential propensities to 
respond to WNT inhibition during differentiation, and consequently are fated to produce 
iPSC-CVPC samples with different proportions of CMs and EPDCs. As iPSCs in the 
iPSCORE collection have passed standard quality checks to confirm their pluripotency 
and genomic integrity 12,19, these transcriptomic expression differences associated with 
cardiac lineage outcome are not detected using current quality metrics. In conclusion, our 
findings suggest that to derive human iPSC lines that respond similarly in differentiation 
protocols, it may be necessary to improve reprogramming methods such that the 
transcriptome and X chromosome activation state is fully reset to the naïve state, and 
incorporate inactivation of one of the X chromosomes in female lines as an early step in 
differentiation protocols. 
 
1.5 Experimental procedures 
Subject information and whole genome sequencing 
Individuals (108 female and 73 male) were recruited as part of the iPSCORE 
project 19 and included 7 MZ twin pairs, members of 32 families (2-10 members/family) 
and 71 singletons and were of diverse ancestries. Subject descriptions including subject 
sex, age, family, ethnicity and cardiac diseases were collected during recruitment. As 
previously described 1, we generated whole genome sequences from the blood or skin 
fibroblasts of the 181 subjects on the HiSeqX (Illumina; 150 bp-paired end).   
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iPSC derivation and somatic mutation analysis 
As previously described, we reprogrammed fibroblast samples using non-
integrative Cytotune Sendai virus (Life Technologies) and the 191 iPSCs (7 subjects had 
2 or more clones each) were shown to be pluripotent and to have high genomic integrity 
with no or low numbers of somatic copy-number variants (CNVs) 19,34.  
 
Large-scale derivation of iPSC-CVPC samples  
To generate iPSC-derived cardiovascular progenitors (iPSC-CVPCs) we used a 
small molecule cardiac differentiation protocol 4. The 25-day differentiation protocol 
consisted of five phases, the optimizations for each step are described in detail below: 1) 
expansion: we developed the ccEstimate algorithm to automate the detection of 80% 
confluency for iPSCs in T150 flasks; 2) differentiation: we tested whether increasing the 
dosage of IWP-2 to induce to inhibit the WNT pathway improved differentiation 
efficiency and found that 7.5 µM at D3 of  the differentiation provided in a single dose 
for 48 hours results in the most efficient differentiation; 3) purification: since fetal 
cardiomyocytes use lactate as primary energy source and have a higher capacity for 
lactate uptake than other cell types 35,36, we incorporated lactate metabolic selection for 
five days to improve iPSC-CVPC purity 14; 4) recovery: after metabolic selection, iPSC-
CVPCs were maintained in cell culture for five days; and 5) harvest: we collected iPSC-
CVPCs at D25 for downstream molecular assays and cryopreserved live cells. 
The 232 attempted differentiations of the 191 iPSC lines were performed as 
follows: 
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Expansion of iPSC: One vial of each iPSC line was thawed into mTeSR1 
medium containing 10 μM ROCK Inhibitor (Sigma) and plated on one well of a 6-well 
plate coated overnight with matrigel. During the expansion phase, all iPSC passaging was 
performed in mTeSR1 medium containing 5 μM ROCK inhibitor, when cells were 
visually estimated to be at 80% confluency. The iPSCs were passaged using Versene 
(Lonza) from one well into three wells of a 6-well plate. Next, the iPSCs were passaged 
using Versene onto three 10 cm dishes at 2.54x104 per cm2 density. The iPSCs 
molonalyer was plated onto three T150 flasks at the density of 3.66 x 104 per cm2 using 
Accutase (Innovative Cell Technologies Inc.). Prior to expansion with Versene, after 
thaw iPSCs were passaged 1-2 times using Dispase II (20mg/ml; Gibco/Life 
technologies). iPSCs were at passage 22.7 ± 4.8 (range 17 to 44) at the monolayer stage 
(i.e., initiation of differentiation).  
 
Differentiation: At 80% iPSC confluency (measured using ccEstimate, see 
section below “Estimation of optimal time for initiation of iPSC-CVPCs differentiation 
using ccEstimate”) cell lysates were collected from 32 lines for RNA-seq data generation, 
where these iPSC and subsequent generated molecular data are referred to as D0 iPSC. 
After reaching 80% confluency (usually within 4-5 days), differentiation was initiated 
with the addition of the medium containing RPMI 1960 (gibco-life technologies) with 
Penicillin – Streptomycin (Gibco/Life Technologies) and B-27 Minus Insulin (Gibco/Life 
Technologies) (hereafter referred to as RPMI Minus supplemented with 12μM CHIR-
99021 (D0). After 24h of exposure to CHIR-99021, medium was changed to RPMI 
Minus (D1). On D3 medium was changed to 1:1 mix of spent and fresh RPMI Minus 
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supplemented with 7.5μM IWP-2 (Tocris). On D5, after 48h of exposure to IWP-2, the 
medium was change to RPMI Minus. On D7, medium was changed to RPMI 1960 with 
Penicillin – Streptomycin (Gibco/Life Technologies) and B-27 Supplement 50X 
(hereafter referred to as RPMI Plus) (Gibco/Life Technologies). Between D7 and D13, 
RPMI Plus medium was changed every 48h.  
 
Purification: On D15 the cells were collected from the flask using Accutase and 
plated onto fresh T150 flasks at confluency 1-1.3 x 106 per cm2. On D16, cells were 
washed with PBS without Ca2+ and Mg2+ (Gibco/Life Technologies) and medium was 
changed for RPMI 1960 no glucose (Gibco/Life Technologies) supplemented with Non-
Essential Amino Acids (Gibco/Life Technologies), L-Glutamine (Gibco/Life 
Technologies), Penicillin-Streptomycin 10,000U (Gibco/Life Technologies) and 4mM 
Sodium L-Lactate (Sigma) in 1M HEPES (Gibco/Life Technologies). Medium 
supplemented with lactate was changed on D17 and D19.  
 
Recovery: On D21 cells were washed with PBS and medium was changed for 
RPMI Plus. On D23 medium was again changed for RPMI Plus. The first beating cells 
were usually observed between D7 and D9 and as early as D7 (immediately after the 
media change) and robust beating was usually observed between D8 and D11. During the 
lactate selection iPSC-CVPC were beating robustly less than 16 hours after reseeding. 
For all successfully derived iPSC-CVPCs on D25, total-cell lysate material was collected 
and frozen for downstream RNA-seq assays. 
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Harvest: On D25 cells were collected using Accutase and processed for the 
following molecular material for downstream assays: 1) cell lysates (RNA-Seq); 2) 
permeabilized cells (ATAC-Seq); 3) live frozen cells (scRNA-seq); 4) cross-linked cells 
(ChIP-Seq, median number of vials/iPSC line = 3; ~1.0 x 107 cells/vial), and 5) dry cell 
pellets (methylation and protein). RNA-seq was generated from 180 iPSC-CVPC 
differentiations (149 lines from 139 subjects) that successfully reached D25. 
 
Estimation of optimal time for initiation of iPSC-CVPCs differentiation using 
ccEstimate 
Heterogeneity of growth rates across different iPSC lines could result in different 
confluency at the monolayer stage (i.e., faster growing lines will be more confluent) and 
hence impact differentiation outcome. To reduce the effects of the iPSC lines having 
different growth rates, we developed an automatic pipeline that analyzes images of 
monolayer-grown cells, determines their confluency and predicts when cells reach 80% 
confluency to initiate the differentiation protocol. Cell confluency estimates (ccEstimate) 
are performed by first dividing each T150 flask into 10 sections and acquiring images for 
each section every 24 hours after cells are plated as a monolayer. The final image is 
acquired immediately after treatment with CHIR, which occurs when their confluence is 
at least 80% (Day 0). The time required for cells to reach 80% confluence is estimated on 
the basis of the confluence curve derived for each section in each flask. To digitally 
measure iPSC confluency, ccEstimate performs image analysis using the EBImage 
package in R 37. Images are read using the readImage function. As lighting may be 
different between the center and the border of an image, only the central part of the image 
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is retained. To separate cells from the background and calculate confluence (i.e. the 
fraction of the surface of the flask that is covered by cells) the following operations are 
performed: 
1. The image is transformed to monochromatic by determining the intensity of each 
pixel as the average of the intensities of the red, green and blue channels. 
2. Edges are sharpened using high-pass filter. The matrix used for this filter is 
15x15 with values -1 on the diagonals and +28 in the center.  
3. Contrasts are enhanced by multiplying the pixel intensities by 2. 
4. Mean and standard deviation of the pixel intensities are calculated. The image is 
transformed from monochromatic to binary by setting all pixels with intensity 
more than two standard deviations higher than the mean to white (intensity = 1) 
and all other pixels to black (intensity = 0).  
5. The resulting binary image is dilated using a disc-shaped structuring element 
with diameter 5 pixels. 
6. 1,000 50x50 pixels sub-images are randomly selected. For each sub-image, the 
number of white pixels is calculated. Confluence is estimated as the fraction of 
the randomly selected sub-images with at least 50% of white pixels.  
Confluency measurement data is collected for at least the first three days after plating 
as monolayer to train a generalized linear model (GLM) using the function glm in R to 
estimate when cells must be treated with CHIR. Estimation is performed separately for 
each flask section and CHIR is added to all three flasks associated to a given line when at 
least 75% of sections have confluence 80%. 
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Using ccEstimate, we could start differentiation at the same confluency level for each 
iPSC sample, thereby reducing or neutralizing the effects of different growth rates. On 
average, each sample required 4.23 ± 1.12 days to reach 80% confluency. The correlation 
between the number of days required to reach 80% confluency and the %CM population 
was -0.05, suggesting that iPSC growth rate does not affect differentiation outcome.  
 
Flow cytometry  
On D25 of differentiation, iPSC-CVPCs were stained with cTnT antibody, 
acquired using FACS and analyzed using FlowJo V10.2. Immunofluorescence analysis of 
iPSC-CVPCs Immunofluorescence was assessed in 5 iPSC-CVPC lines. Live frozen 
iPSC-CVPC harvested on D25 were thawed, plated for five days, fixed, permeabilized 
and incubated with antibodies.  
 
Generation of RNA-seq data 
For gene expression profiling of iPSCs, we used RNA-seq data from 184 samples 
(cell lysates collected between passages 12 to 40). For gene expression profiling of iPSC-
CVPCs, we generated RNA-seq data from 180 samples at D25 differentiation. All RNA-
seq samples were generated and analyzed using the same pipeline to obtain transcript per 
million bp (TPM) 1.  
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Generation of scRNA-seq data 
To capture the full spectrum of heterogeneity among the iPSC-CVPCs, we 
selected eight samples with variable %cTnT (42.2 to 95.8%). After removing 
proliferating cells and doublets we obtained 34,905 cells. 
 
CIBERSORT 
Expression levels of the top 50 genes overexpressed in each of the three cell 
populations (total 150 genes) were used as input for CIBERSORT 16 to calculate the 
relative distribution of the three cell populations for the 180 iPSC-CVPC samples at D25.  
 
Characterizing transcriptional similarities of iPSCs, iPSC-CVPCs and GTEx adult 
tissues  
We performed principle component analysis on RNA-seq on 184 iPSCs, 180 
iPSC-CVPCs and 1,072 RNA-seq samples from GTEx.  
Determining optimal CM:EPDC ratio estimates from CIBERSORT to define iPSCs 
cardiac fates 
To obtain the optimal threshold, we conducted a series of differential expression 
analyses on 15,228 autosomal genes in the 184 iPSC lines (147 completed and 37 
terminated) considering the ratio of population frequencies at ten thresholds. The 30:70 
(CM:EPDC) ratio resulted in the highest number of differentially expressed genes (84 
genes with Storey q-value < 0.1, t-test), which is substantially greater than random 
expectation. Thus, we grouped the 184 iPSC lines into: 1) those that have CM fates, i.e. 
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produced iPSC-CVPC with >= 30% Population 1, and 2) those that have EPDC fates, i.e. 
produced iPSC-CVPC with > 70% Population 2.  
 
Comparing the number of differentially expressed genes with random expectation 
To determine if the number of significantly differentially expressed genes was 
higher than expected by chance, we shuffled the assignments of the 184 iPSC RNA-seq 
samples to differentiation fate (125 CM and 59 EPDC) 100 times.  
 
Contribution of 91 signature genes in iPSCs to determination of cardiac fate  
For each of the 91 signature genes, we built a GLM with the expression of the 
gene as input and the differentiation outcome (e.g. % Population 1) as output using a logit 
link function. To understand the cumulative contribution of all 91 signature genes on 
cardiac differentiation fate, we built a GLM with an L1 norm penalty using the 
expression of all 91 genes as input and the differentiation outcome as output using. To 
avoid overfitting the model, we used a 10-fold cross validation. 
 
Detecting associations between genetic background and differentiation outcome 
We obtained genotypes for 8,620,159 biallelic SNPs and short indels with allelic 
frequency >5% in the iPSCORE collection. Genotypes were obtained for each SNP in all 
individuals using bcftools view 38. Linear regression was used to calculate the associations 
between the genotype of each variant and differentiation outcome (% CM population in 
the iPSC-CVPCs), using passage at monolayer and sex as covariates. 
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Gene set enrichment analysis using the MSigDB collection 
We performed GSEA using the R gage package 39 on all MSigDB gene sets 20. 
FDR correction was performed independently for each collection. The normalized mean 
expression difference between iPSCs that differentiated to CMs and iPSCs that 
differentiated to EPDCs was used as input for GSEA.  
 
Associations between iPSC and subject features and differentiation outcome 
A GLM was built in R using age, sex, ethnicity, age, and passage of the iPSCs at 
D0 of differentiation as input and differentiation outcome as output (0 = EPDCs; and 1 = 
CMs).  
 
Identifying X chromosome inactivation in female iPSCs and iPSC-CVPCs 
To analyze X chromosome inactivation, we used 113 female iPSCs, of which 87 
where CM-fated and 26 were EPDC-fated. We called ASE in RNA-Seq from iPSC and 
iPSC-CVPCs as previously described 1. Genes lying in X chromosome pseudoautosomal 
(PAR) regions (PAR1: 60001- 2699520, PAR2: 154931044 – 155260560) were removed 
from analysis. We defined the strength of ASE for each gene as the fraction of RNA 
transcripts that were estimated to originate from the allele with higher expression 
(referred to as allelic imbalance fraction, AIF).  
 
Validation of findings in Yoruba iPSC set 
The Yoruba iPSCs 12 were generated from LCLs using episomal reprogramming. 
Differentiation was performed using a small molecular method and iPSC-CMs were 
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harvested on D31 or D32. 15 lines successfully generated iPSC-CMs and 24 were 
terminated on or before day 10. We downloaded RNA-seq for 34 of the Yoruba iPSC and 
13 iPSC-CM samples from Gene Expression Omnibus (GEO; GSE89895), as well as 297 
samples from 19 distinct iPSCs in a timecourse experiment (day 0-15) performed on the 
same Yoruba iPSC samples 22. RNA-seq was aligned using STAR, gene expression was 
quantified using the RSEM package and normalized to TPM. The RNA-seq for the 13 
Yoruba iPSC-CMs and from all timecourse time points were analyzed using 
CIBERSORT similar to the iPSCORE samples.  
 
1.6 Data and software availability 
 
Accession numbers for the RNA-seq data, scRNA-seq, and WGS genotypes are 
dbGaP: phs00924 and phs001325. The 191 iPSC lines are available through WiCell 
Research Institute: https://www.wicell.org/; NHLBI Next Gen Collection. 
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Chapter 2: Cellular deconvolution of GTEx tissues powers eQTL 
studies to discover thousands of novel disease and cell-type 
associated regulatory variants 
 
2.1 Abstract 
 
The Genotype-Tissue Expression (GTEx) resource has contributed a wealth of 
novel insights into the regulatory impact of genetic variation on gene expression across 
human tissues, however thus far has not been utilized to study how variation acts at the 
resolution of the different cell types composing the tissues. To address this gap, using 
liver and skin as a proof-of-concept tissues, we show that readily available signature 
genes based on expression profiles of mouse cell types can be used to deconvolute the 
cellular composition of human GTEx tissues. We then deconvoluted 6,829 bulk RNA-seq 
samples corresponding to 28 GTEx tissues and show that we are able to quantify cellular 
heterogeneity, determining both the different cell types present in each of the tissues and 
how their proportions vary between samples of the same tissue type. Conducting eQTL 
analyses for GTEx liver and skin samples using cell type composition estimates as 
interaction terms, we identified thousands of novel genetic associations that had lower 
effect sizes and were cell-type-associated. We further show that cell-type-associated 
eQTLs in skin colocalize with melanoma, malignant neoplasm, and infection signatures, 
indicating variants that influence gene expression in distinct skin cell types play 
important roles in skin traits and disease. Overall, our study provides a framework to 
estimate the relative fractions of different cell types in GTEx tissues using signature 
genes from mouse cell types and functionally characterize human genetic variation that 
impacts gene expression in a cell-type-specific manner. 
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2.2 Introduction 
 
Understanding the regulatory impact of genetic variation on complex traits and 
disease has been a longstanding goal of the field of human genetics. To decipher the 
mechanistic underpinnings of complex traits, the GTEx Project17 has generated a large 
dataset, including over 10,000 bulk RNA-seq samples representing 53 different tissues 
(corresponding to 30 organs) obtained from 635 genotyped individuals, to link the 
influence of genetic variants on gene expression levels through expression quantitative 
trait loci analysis (eQTL). While GTEx has provided important biological insights, 
unaccounted for cellular heterogeneity (i.e., different cell types within a tissue and the 
relative proportions of each cell type across samples of the same tissue) present in bulk 
RNA-seq can affect genotype-gene expression associations40. Since regulation of gene 
expression varies across cell types, not accounting for cellular composition could result in 
loss or distortion of signal from relatively rare cell types, thus characterization of cellular 
heterogeneity across all GTEx tissues is critical for more comprehensive eQTL studies. It 
is possible that future studies pursuing cell-type-associated eQTLs may utilize single cell 
approaches (e.g. single cell RNA-seq; scRNA-seq); however, non-trivial technical 
challenges, such as hard to dissociate tissues and low capture efficiencies, make the 
generation of a GTEx-scale single-cell expression dataset a substantial undertaking, 
which would take years to complete. Thus, as single-cell large-scale scRNA-seq 
collections progress, our present knowledge of how genetic variation influences cell-
type-associated gene expression would greatly benefit from conducting eQTL analyses 
on bulk GTEx tissue samples whose cellular heterogeneity has been characterized 
through existing deconvolution methods16,41,42. 
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To characterize the heterogeneity of bulk RNA-seq samples, gene signatures 
from cell types known to be present in a given tissue can be used to deconvolute the 
cellular composition (i.e. the proportion of each cell type). The signature genes needed to 
deconvolute a heterogeneous tissue can be obtained by analyzing scRNA-seq generated 
from an analogous tissue. However, there are relatively few human scRNA-seq resources 
currently available43-47, and thus only a small fraction of GTEx tissues could be 
deconvoluted using gene expression signatures derived from existing human single-cell 
data. While human single-cell data is limited, the Tabula Muris exists48, which is a 
powerful resource of scRNA-seq data from mouse including more than 100,000 cells 
from 20 tissue types (referred in the Tabula Muris resource as organs and tissues). A 
recent study showed that similar cell types in humans and mice share sufficient gene 
expression signatures to integrate scRNA-seq data between the two species49, raising the 
possibility of utilizing the available scRNA-seq from mouse to generate the gene 
expression signatures for deconvolution of GTEx tissues.  
To examine the feasibility of using mouse-derived gene expression signatures to 
deconvolute human tissues, we compared cellular composition estimates of GTEx liver 
and GTEx skin samples generated using human scRNA-seq to those generated using the 
Tabula Muris scRNA-seq resource. We show that the human and mouse single-cell data 
captured many overlapping cell populations and that using either human-derived or 
mouse-derived gene signatures to deconvolute the 175 GTEx liver samples and the 860 
GTEx skin samples resulted in highly correlated estimated cellular compositions. We 
show that the main differences between the cell types identified using the human-derived 
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versus mouse-derived signature genes were due to: 1) subtle biological differences that 
exist in human and mouse immune cells, and 2) resolution (i.e., the ability to detect less 
abundant cell types and distinguish between similar cell types) which was impacted by 
technical differences in the human and mouse scRNA-seq data sets, including the number 
of cells captured and subjected to scRNA-seq and the spatial location from which the 
tissue was sampled. We used gene signatures derived from the Tabula Muris resource to 
deconvolute 6,829 GTEx samples corresponding to 28 tissues from 14 organs, which 
enabled us to determine how the fractions of different cell types vary across GTEx 
samples derived from the same tissue. Using deconvoluted liver and skin GTEx samples 
for eQTL analyses, we identified thousands of novel (i.e. not detected using bulk RNA-
seq samples) genetic associations that tended to have lower effect sizes, some of which 
are cell-type-associated. Finally, we show that skin cell-type-associated eQTLs colocalize 
with GWAS variants for melanoma, malignant neoplasm, and infection signatures, 
indicating that variants that are functional in limited skin cell types may play major roles 
in skin traits and disease. Taken together, our study demonstrates two major principles: 1) 
mouse-derived signature genes can be used to deconvolute the cellular composition of 
human tissues; and 2) the estimation of cellular heterogeneity by deconvolution enhances 
the genetic insights yielded from the GTEx resource. 
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2.3 Results 
 
2.3.1 scRNA-seq from mouse and human analogous tissues capture similar cell types  
 
To examine the extent to which scRNA-seq generated from analogous human 
and mouse tissues (Table 2.1) captured similar cell types, we first examined liver as a 
proof-of-concept tissue (Figure 2.1a, “proof-of-concept”). We used previously defined 
cell types from Tabula Muris mouse liver cells (which were purified for viable 
hepatocyte and non-parenchymal cells followed by FACS sorting; 710 cells; 5 cell 
types)48, and to be consistent, we used the Tabula Muris annotation approach to analyze 
existing human liver scRNA-seq data (total liver homogenate; 8,119 cells; 15 cell 
types)43. In brief, on the 8,119 human liver single-cells, we performed nearest-neighbor 
graph-based clustering on components computed from principal component analysis 
(PCA) of variably expressed genes, and then used marker genes to define the cell 
populations corresponding to each of the 15 previously observed cell types 43. 
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Table 2.1 Mapping of Tabula Muris scRNA-seq tissues/organs used to 
deconvolute human GTEx tissues 
GTEx issue Tabula Muris organ 
Aorta Heart (aorta subset) 
Artium Heart (left and right atrium subset) 
Bladder Bladder 
Amygdala Brain-nonmicroglia 
Anterior cinglulat cortex (BA24) Brain-nonmicroglia 
Caudate (basal ganlia) Brain-nonmicroglia 
Cerebellar Hemisphere Brain-nonmicroglia 
Cerebellum Brain-nonmicroglia 
Cortex Brain-nonmicroglia 
Frontal cortex (BA9) Brain-nonmicroglia 
Hippocampus Brain-nonmicroglia 
Hypothalamus Brain-nonmicroglia 
Nucleus accumbens (basal ganglia) Brain-nonmicroglia 
Putamen (basal ganglia) Brain-nonmicroglia 
Spinal cord (cervical c-1) Brain-nonmicroglia 
Substantia nigra Brain-nonmicroglia 
Colon - Sigmoid Colon 
Colon - Transverse Colon 
Adipose - Subcutaneous Fat 
Adipose - Visceral (Omentum) Fat 
Kidney - Cortex Kidney 
Liver Liver 
Mammary Mammary 
Skeletal muscle Muscle 
Pancreas Pancreas 
Skin - not sun exposed Skin 
Skin - sun exposed Skin 
Spleen Spleen 
Ventricle Heart (left and right ventricle subset) 
 
  
  
 
57 
 
Human and mouse scRNA-seq from liver captured several shared cell types, 
including hepatocytes, endothelial cells, and various immune cells (Kuppfer cells, B 
cells, and natural killer (NK) cells) (Figure 2.1b-e), however we noted that there were 
many more distinct cell types for human liver. This was due to the fact that cell type 
resolution (i.e. the ability to distinguish between similar cell types) can be influenced by 
1): the number of cells captured and subjected to scRNA-seq, which may influence the 
proportion of observed common or rare cell types50; and 2) how the tissue was sampled, 
which may enrich for selected populations or capture how populations are distinguished 
by spatial location (i.e. zonation). Some of the 15 cell types identified in the human liver 
scRNA-seq were highly similar and clustered near each other, for example there were 
four hepatocytes populations and two endothelial cell populations (human periportal 
sinusoidal endothelial cells (SEC) and central venous SECs) distinguished by their 
zonation (Figure 2.1b,c). In contrast, for the mouse liver scRNA-seq, which had 
considerably fewer cells analyzed, we only observed one hepatocyte population and one 
endothelial population (Figure 2.1d,e). If we collapsed the cell types that were similar to 
each other in the human scRNA-seq, we obtained 7 distinct cell classes (Figure 2.1b,f), 
which largely corresponded to the 5 cell types from mouse liver scRNA-seq 
(cholangiocytes and hepatic stellate cells were absent due to having been sorted by 
FACS; Figure 2.1d-f). Overall, these results show that scRNA-seq generated from human 
and mouse liver captured similar cell types and that technical differences, including the 
number of cells analyzed and tissue sampling methodology, affects the cell type 
resolution.  
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2.3.2 Mouse liver signature genes can estimate cellular composition of human liver 
samples 
To establish the ability to use expression profiles of signature genes derived from 
mouse scRNA-seq for the deconvolution of human GTEx tissues, we first examined if the 
similarly annotated cell types identified in the two species (Figure 2.1b-e) clustered 
together based on their gene expression profiles. We harmonized the human and mouse 
liver scRNA-seq using canonical correlation analysis (CCA) and visualized using 
uniform manifold approximation and projection (UMAP) (Figure 2.2a,b). We observed 
that the corresponding cell types across the two species clustered closely together, 
indicating that they had highly similar gene expression profiles. 
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Figure 2.1 Human and mouse liver scRNA-seq contains similar cell types 
(a) Overview of the study design. We first conducted proof-of-concept analyses, where we 
compared cellular estimates of two proof-of-concept GTEx tissues (liver and skin) after having 
deconvoluted each using both mouse and human signature genes obtained from scRNA-seq. We 
then performed cellular deconvolution of the 28 GTEx tissues from 14 organs using CIBERSORT 
and characterized both the heterogeneity in cellular composition between tissues and the 
heterogeneity in relative distributions of cell populations between RNA-seq samples from a given 
tissue. Finally, we used the cell type composition estimates as interaction terms for eQTL analyses 
to determine if we could detect novel cell-type-associated genetic associations. (b)  UMAP plot of 
clustered scRNA-seq data from human liver. Each point represents a single cell and color coding 
of cell type populations (See Methods: Defining the cellular composition of liver) are shown 
adjacent (Figure 2.1c). Similar cell types can be collapsed to single cell type classifications and are 
noted with colored, transparent shading (Figure 2.1f). (c) Bar plots showing the fraction of each 
cell type from the scRNA-seq data from human liver. Color-coding of cell types correspond to the 
colors of the single cells in Figure 2.1f. (d) UMAP plot of clustered scRNA-seq data from mouse 
liver. Each point represents a single cell and color coding of cell type populations are shown 
adjacent (Figure 2.1e). Each cell type has a corresponding collapsed cell type in human liver and is 
noted with colored, transparent shading (Figure 2.1f). (e) Bar plots showing the fraction of each 
cell type from the scRNA-seq data from mouse liver. Color-coding of cell types correspond to the 
colors of the single cells in Figure 2.1d. (f) Legend showing the colors of collapsed similar cell 
types from human liver (transparent shading in UMAP Figure 2.1b,d). All cell types from mouse 
liver have a corresponding collapsed cell type in human liver (hepatocyte, endothelial, 
macrophages, B cell, NK/NKT cell) and human liver also contains two additional cell types not 
present in mouse (cholangiocytes and hepatic stellate cells). 
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Figure 2.2 Comparison of GTEx liver cell estimates using mouse versus human signature 
gene 
(a) UMAP plot of integrated scRNA-seq data from human and mouse liver. Each point represents 
a single cell and color coding of cells indicates the species the cells were obtained from (human = 
green; mouse = purple). (b) UMAP plot of integrated scRNA-seq data from human and mouse 
liver. Each point represents a single cell and color coding of cell type populations are shown in the 
adjacent legend. The collapsed populations are the same as those shown in Figure 2.1f. (c,d,e) Bar 
plots showing the fraction of cell types estimated in the 175 GTEx liver RNA-seq samples 
deconvoluted using gene expression profiles from high resolution human liver scRNA-seq (C), 
low resolution mouse liver scRNA-seq (D), and GTEx estimates generated by collapsing high 
resolution human cell types within each of the 7 distinct cell classes (E). (f) Heatmap showing the 
correlation of GTEx liver cell population estimates from human liver scRNA-seq at high and 
collapsed resolutions (rows) and mouse liver (columns) at low resolution. Color coding of 
heatmap scales from red, indicating negative correlation in estimates, to blue, indicating positive 
correlation in estimates. Significance is indicated with asterisks. (g, h) Scatter plots of estimated 
cell compositions across 175 GTEx livers deconvoluted using human scRNA-seq for human 
hepatocyte 0 population (d) and human collapsed endothelial cells (e) versus estimated cell 
populations deconvoluted using mouse scRNA-seq. 
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We next compared the cellular composition estimates of 175 GTEx bulk liver 
RNA-seq samples17 obtained by deconvolution using human signature genes to those 
obtained using mouse signature genes (Figure 2.1a, “proof-of-concept”), which 
respectively consisted of the top 200 most significantly overexpressed genes for each cell 
type identified in scRNA-seq from high resolution human liver (i.e. signature genes from 
15 cell types) and low resolution mouse liver (i.e. signature genes from 5 cell types). 
From the 175 GTEx bulk liver RNA-seq samples, we independently extracted the 
expression of the signature genes at the two resolutions, and used CIBERSORT16 to 
estimate the cellular compositions (i.e. high resolution human liver estimates and low 
resolution mouse liver estimates) (Figure 2.2c,d). To investigate how resolution impacted 
the correlation between human and mouse signature gene estimates, we also collapsed the 
high resolution human liver cellular composition estimates for each of the 175 
deconvoluted samples by summing the estimates across similar cell types in each of the 7 
distinct cell classes (Figures 2.1b,f and 2.2e). We then calculated all pairwise-correlations 
between each of the estimated cell populations in the 175 GTEx liver samples from 
human (high and collapsed resolution estimates) with the estimated cell populations from 
mouse (low resolution estimates) (Figure 2.2f). We found that hepatocyte estimates from 
mouse liver were positively and highly correlated with the human high resolution 
hepatocyte 0 population estimate (r = 0.71, p-value = 5.4x10-28), but not correlated with 
any of the other three high resolution hepatocyte populations (1, 3 and 4); and was 
slightly less correlated with the collapsed hepatocyte population estimate (r = 0.64, p-
value = 1.015x10-21) (Figure 2.2f,g). This indicates that the low resolution mouse 
hepatocyte population corresponds to one of the four human hepatocyte 
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populations/zones potentially due to tissue sampling. Further, we observed that the 
endothelial estimates from mouse were highly correlated with the collapsed human 
endothelial population estimates (r = 0.98, p-value = 1.2x10-115) but not correlated with 
either high resolution human periportal SECs or central venous SECs (Figure 2.2h). This 
indicates that the human endothelial population estimates captured a higher resolution of 
cell type specificity (i.e. two independent endothelial zones), whereas the mouse 
endothelial population estimates likely captured a mixture of both cell types (i.e. the two 
endothelial zones are combined into a single cell population), which is potentially due to 
the lower number of mouse cells analyzed. While in general we observed high correlation 
in the human and mouse population estimates for most cell types (hepatocytes, 
endothelial cells, and Kupffer cells), B cells were non-significantly correlated, and NK-
like cells were negatively correlated (Figure 2.2f). This difference in immune cell 
estimates in GTEx liver is not wholly unexpected, as biological differences, including 
immune response differences, exist between species 51. To further examine the accuracy 
of the deconvolution, we conducted simulations to obtain 100 human liver samples with 
known cell type distributions, and confirmed that the estimated cell population 
distributions obtained using both human and mouse gene expression signatures were 
consistent with their expected values (Figure 2.3a,b).  Our results show that, while 
technical differences in scRNA-seq generation and biological differences between 
humans and mice may impact cell estimation performance, overall mouse signature genes 
can be used to deconvolute human GTEx bulk RNA-seq samples. 
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Figure 2.3 Testing the accuracy of deconvolution using simulated samples of known cell type 
distributions 
Plots showing the correlation between 100 simulated samples with known cell type distributions 
cell types (rows) and cell type estimates from human and mouse cell types (columns) for (a) all 
cell types and (b) collapsed cell types. For most cell types, we observed high correlation (r > 0.6) 
between the known cell type distributions and the population estimates obtained by deconvolution 
using human and mouse expression signatures. There were two exceptions: 1) human stellate cells 
(r = 0.572 between human estimates and known cell type distributions), likely because their gene 
expression signatures were derived from only 79 cells; and 2) B-cells (r = 0.363 between mouse 
estimates and known cell type distributions), consistent with between-species immune system 
differences. 
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2.3.3 Deconvolution of GTEx skin confirms mouse signature genes can estimate 
cellular composition 
To examine the similarity of cellular estimates across 860 GTEx human skin 
samples obtained using human-derived versus mouse-derived signature genes, we used 
scRNA-seq from human epidermal cells52 (digested dorsal forearm skin biopsies; 5,670 
cells; 9 cell types) (Figure 2.4a,b) and Tabula Muris mouse skin cells (FACS sorted 
epidermal keratinocytes; 2,263 cells; 6 cell types) (Figure 2.4c,d). While the previous 
human and mouse liver scRNA-seq studies43,48 used similar naming conventions for the 
cell type annotations (Figure 2.1b-e), the human and mouse skin scRNA-seq studies48,52 
did not (Figure 2.4a-d), and thus we first needed to identify the corresponding cell types 
across the two species. To accomplish this, we harmonized the human dermis and mouse 
skin scRNA-seq using CCA (Figure 2.4e,f) and visualized using UMAP. We observed 
three distinct superpopulations: 1) superpopulation 1, epidermal cells, consisting of the 
four human keratinocyte populations (14, 5, 711, and 1) and mouse epidermal cells, basal 
cells, stem cells of epidermis, and outer bulge cells (keratinocyte stem cells), 2) 
superpopulation 2, consisting of the three human fibroblast populations (0, 3, and 4) and 
mouse inner bulge cells (keratinocyte stem cells); and 3) superpopulation 3, leukocytes, 
consisting of human lymphocytes and mouse leukocytes (Figure 2.4e,f). Further, the 
different cell types within each of the three clusters expressed corresponding marker 
genes, confirming that they indeed were similar cell types in the human and mouse skin 
scRNA-seq. Overall, we found human and mouse skin scRNA-seq captured shared cell 
types that cluster into three distinct superpopulations. 
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Figure 2.4 Testing the accuracy of deconvolution using simulated samples of known cell type 
distributions 
 (a) UMAP plot of clustered scRNA-seq data from human epidermis. Each point represents a 
single cell and color-coding of cell type populations are shown adjacent (Figure 2.4b). (b) Bar 
plots showing the fraction of each cell type from the scRNA-seq data from human epidermis. 
Color-coding of cell types correspond to the colors of the single cells in Figure 2.4a. (c) UMAP 
plot of clustered scRNA-seq data from mouse skin. Each point represents a single cell and color-
coding of cell type populations are shown adjacent in Figure 2.4d. (d) Bar plots showing the 
fraction of each cell type from the scRNA-seq data from mouse skin. Color-coding of cell types 
correspond to the colors of the single cells in Figure 2.4c. (e) UMAP plot of integrated scRNA-seq 
data from human epidermis and mouse skin. Each point represents a single cell and color-coding 
of cells indicates the species the cells were obtained from (human = green; mouse = purple). (f) 
UMAP plot of integrated scRNA-seq data from human epidermis and mouse skin. Each point 
represents a single cell and color coding of cell type populations and collapsed superpopulations 
are shown in the adjacent legend. (g,h) Bar plots showing the fraction of cell types estimated in 
GTEx skin RNA-seq samples from human epidermis scRNA-seq (g) and mouse skin scRNA-seq 
(h). (i) Heatmap showing the correlation of GTEx skin cell population estimates from mouse skin 
scRNA-seq at high and collapsed resolutions (rows) and human skin (columns). Color-coding of 
heatmap scales from red, indicating negative and low correlation in estimates, to blue, indicating 
positive and high correlation in estimates. Significance is indicated with asterisks. (j,k) Scatter 
plots of estimated cell compositions across 860 GTEx skin samples deconvoluted using human 
scRNA-seq for human keratinocyte 14 population versus mouse stem cell of epidermis population 
(j) and keratinocyte 1, 5, 14, 711 population versus collapsed mouse epidermal cell populations 
(k). 
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We next compared the cellular composition estimates of 860 GTEx bulk skin 
RNA-seq samples17 obtained by deconvolution using human gene expression signatures 
to mouse gene expression signatures (Figure 2.1a, “proof-of-concept”). We obtained 
signature genes for each cell type identified in scRNA-seq from human skin (i.e. 
signature genes from each of 9 dermis cell types) and mouse skin (i.e. signature genes 
from each of 6 skin cell types) and used CIBERSORT to deconvolute the 860 GTEx skin 
RNA-seqs (Figure 2.4g,h). Given the presence of the three superpopulation clusters 
observed in the mouse and human scRNA-seq integration analysis (Figure 2.4f), similar 
to liver, we investigated how resolution impacted the correlation between human and 
mouse signature gene estimates. We independently collapsed the high resolution human 
epidermis (9 cell types) and the high resolution mouse skin (6 cell types), by summing 
the estimates across the cell types in each of the three distinct superpopulations. We then 
calculated all pairwise-correlations between each of the estimated cell populations in the 
860 GTEx skin samples from human estimates (high and collapsed) with the estimated 
cell populations from mouse (high and collapsed resolution) (Figure 2.4i). Using the 
integration analysis (Figure 2.4f) as a guide, we examined the similarity of estimates 
from human and mouse cell populations mapping to each of the three superpopulations. 
First, we examined the similarity of human cell types in Superpopulation 1 (Keratinocyte 
14, Keratinocyte 5, Keratinocyte 711, Keratinocyte 1, cornified envelope, and collapsed 
estimates of these cell types) and mouse cell types in Superpopulation 1 (epidermal cell, 
basal cell, stem cell of epidermis, outer bulge, and collapsed estimates of these cell types) 
(Figure 2.4f; dark purple shading). We observed the human keratinocyte population 14 
had a strong positive correlation with the mouse stem cell of the epidermis estimates (R = 
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0.89; p = 2.4 x 10-103) (Figure 2.4i,j). We also found that collapsed mouse epidermal cell 
estimates were correlated with collapsed human keratinocyte population estimates (R = 
0.44, p = 1.19 x 10-43) (Figure 2.4i,k). These results indicate that despite differences in 
annotations, estimates from mouse and human cell types mapping to the epidermal cell 
superpopulation are highly correlated. Second, we examined the similarity of human cell 
types in superpopulation 2 (fibroblast 0, fibroblast 3, fibroblast 4, and collapsed estimates 
of these cell types) and the single mouse cell type (inner bulge) in this cluster (Figure 
2.4f; light purple shading). We found that human fibroblast (high resolution and 
collapsed) estimates were not correlated with the mouse inner bulge cell population 
estimates (Figure 2.4i), indicating that, despite similar enough global gene expression 
patterns for the human fibroblasts and mouse inner bulge cells to cluster together, their 
signature genes distinguish them as different cell types during deconvolution. Third, we 
examined the similarity of the human cell type (lymphocyte) and mouse cell type 
(leukocyte) in superpopulation 3 (Figure 2.4f; pink shading). Similar to the liver 
estimates, mouse and human leukocyte estimates were not correlated (Figure 2.4i), likely 
due to known species differences in immune cells. As we observed in liver, we confirmed 
that technical and biological differences influence cell estimate performance, however 
overall cell composition estimates derived from human and mouse skin signature genes 
are correlated, supporting our ability to use mouse scRNA-seq as an alternative to human 
scRNA-seq for the deconvolution of GTEx tissues. 
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2.3.4 Cellular deconvolution of GTEx tissues reveals surprising levels of 
heterogeneity   
To understand the extent to which the mouse signature genes obtained from cell 
types across 14 tissues were able to distinguish between the 28 GTEx tissues, we 
extracted the expression of the signature genes (Table 2.1) across the 6,829 bulk GTEx 
RNA-seq samples and visualized how the samples clustered (Figure 2.5a). We observed 
that the mouse signature genes were able to differentiate between the human GTEx 
organs, as well as illustrated the existence of organ substructures delineating 
heterogeneity in tissues belonging to the same organ. For example, tissues from the same 
organ clustered closely together and distinctly from other organs, including the heart 
tissues (atrium and ventricle), brain tissues (cortex, frontal cortex, hippocampus, anterior 
cingulate cortex, amygdala, substantia nigra, spinal cord, putamen, nucleus accumbens, 
caudate, and hypothalamus), adipose (visceral and subcutaneous), and colon (sigmoid 
and transverse). Of note, within the brain we also observe clustering according to 
zonation, including clustering of samples from the cerebellum and cerebellar hemisphere, 
as well as clustering of samples from the frontal cortex, cortex, and anterior cingulate 
cortex. These results suggest that signature gene capture both organ differences, as well 
differences that exist in tissues from the same organ that hint at tissue substructures 
driven by sample heterogeneity.  
To understand the cellular heterogeneity of 28 GTEx tissues (Figure 2.1a, 
“cellular deconvolution”), we used the signature genes from 14 mouse tissue types (Table 
2.1) to perform cellular deconvolution of 28 GTEx tissues from 14 organs (Figure 2.5b; 
Table 2.1), where the number of samples for each GTEx tissue varied from 11 (bladder) 
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to 860 (skin). We found that all samples were well-deconvoluted (P-value < 0.001; 
CIBERSORT, 1,000 permutations) and that each deconvoluted GTEx tissue contained a 
variable number of cell types ranging from two (bladder) to seven (brain and heart) 
(Figure 2.5c). In ~30% of the tissues (9 out of 28), we found that not all mouse cell types 
were estimated, possibly due to the GTEx tissues having been isolated for bulk RNA-seq 
from a different spatial location than mouse or species differences in cell types. 
Additionally, the relative distribution of the estimated cell types varied between different 
samples of the same tissue (Figure 2.5d). Tissues with the least heterogeneous cell 
population distributions between samples were aorta and spleen, whereas those with the 
most heterogeneous cell population distributions between samples were brain (13 
tissues), colon, and left ventricle. Examining the tissues corresponding to the same organ, 
we noted that some had the same cell types estimated at similar distributions (adipose 
subcutaneous and visceral), some had the same cell types present at variable proportions 
(heart atrial appendage and left ventricle; 13 brain tissues), and others had variable cell 
types present/absent (colon transverse and sigmoid). These results reveal a striking 
heterogeneity in GTEx tissues that has not been previously appreciated and may be 
contributing noise to eQTL analyses.   
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Figure 2.5 Cellular deconvolution of 28 GTEx tissues 
(a) UMAP using the expression of all scRNA-seq derived signature genes across the 28 GTEx 
tissues. (b) Stacked bar plots showing the fraction of cell types estimated in GTEx RNA-seq 
samples from mouse scRNA-seq. (c) Bar plots comparing the number of cell types discovered in 
mouse scRNA-seq (light grey) vs. the number of these cell types that were estimable for each 
GTEx tissue. (d) Box plots showing per RNA-seq sample the distribution of the log2 average 
square distance from the mean estimated cellular compositions for each GTEx tissue.  
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2.3.5 eQTL analyses using deconvoluted tissues increases power   
 
Since we observed heterogeneity in the relative distributions of cell populations 
across GTEx RNA-seq samples, we hypothesized that considering the cell population 
distributions of each sample would improve eQTL analysis by increasing our power to 
detect novel tissue and/or cell type associations (Figure 2.1a). We identified 19,621 
expressed genes in GTEx liver samples and performed one eQTL analysis not 
considering cellular heterogeneity (i.e. bulk resolution), and three eQTL analysis using 
cell population estimates as covariates to adjust for cellular heterogeneity: 1) considering 
high resolution human liver estimates (15 cell types; Figure 2.2a); 2) considering 
collapsed resolution human liver estimates (7 cell types; Figure 2.2c); and 3) considering 
low resolution mouse liver estimates (5 cell types; 2.2b). Using cell population estimates 
as covariates we detected many more genes with significant eQTLs (eGenes) than at bulk 
resolution (Figure 2.6a). We found that considering high resolution estimates identified 
the most eGenes (10,117) with 1.3 fold and 3.1 fold more than collapsed and low 
resolution estimates, respectively. These findings show that conducting eQTL analyses 
using highly resolved cell population estimates as a covariate significantly increases the 
power to identify eGenes. 
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Figure 2.6 Using cellular deconvolution to discover cell-type-associated eQTLs 
(a) Bar plot showing the number of eGenes detected in each eQTL analysis from liver (shades of 
red) and skin (shades of blue). (b,c,d) Distributions of (b) number of GTEx tissues where each 
eGene has significant eQTLs, (c) effect size β and (d) standard error of β in liver and skin. Colors 
are as in panel a. Vertical dashed lines represent mean values. P-values were calculated in 
comparison with the bulk resolution analysis for each tissue using Mann-Whitney U test. (e,f,g,h,i) 
Bar plots showing the number of eGenes significantly associated with each cell population 
considering cell estimates for: liver high resolution (e), liver collapsed resolution (f), liver low 
resolution (g), skin high resolution (h), and skin collapsed resolution (i). Total number of eGenes 
for each cell type indicates the cell type is significantly associated and the hashed number of 
eGenes for each cell type indicates the association is cell-type-specific (e.g. only significant in that 
cell type). In cases where a given cell type had no significant association, the bar is not shown. 
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Given the differences in the number of detected eGenes based on cell-type 
resolution, we hypothesized that eGenes detected at low powered resolutions (bulk and 
collapsed resolution) commonly shared eQTLs with other GTEx tissues (i.e. tissue-
neutral) and the eGenes detected using higher powered resolutions had more tissue-
associated eQTLs (i.e. less frequently in other GTEx tissues). For each resolution, we 
calculated the number of GTEx tissues in which each eGene has eQTLs. We observed 
that eGenes identified using cell populations as covariates in general were more tissue-
associated than eGenes detected at bulk resolution. Compared to bulk resolution, high 
resolution eGenes were the most tissue-associated (p = 4.2x10-194; Mann-Whitney U test), 
then low resolution eGenes (p = 2.17x10-174; Mann-Whitney U test), and collapsed 
resolution was the least tissue-specific (p = 6.59x10-94; Mann-Whitney U test) (Figure 
2.6b), showing that the resolution of cell population estimates used as covariates is 
correlated with the power of the study to identify tissue-associated eGenes.  
Furthermore, using cell populations as covariates resulted in decreased effect size 
(β) (Figure 2.6c) and standard error (SE) of β (Figure 2.6d), where relative to bulk 
resolution, the higher the resolution of the eQTLs, the smaller the β and SE of β. 
However, in general the β values for the top hit for each gene were highly correlated 
between eQTLs detected using cell populations and eQTLs detected without using cell 
populations (r > 0.975). By performing a permutation test, we excluded that the detection 
of a larger number of eQTLs using cell populations was due to the fact that a larger 
number of covariates was used. These results indicate that using cell population 
distributions as covariates overall reduces the noise, thereby potentially increasing our 
power to identify eQTLs. 
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2.3.6 Resolution of deconvoluted tissues impacts the number of identified cell-type-
associated regulatory variants     
To examine if some of the eQTLs identified using cell population estimates as 
covariates were cell-type-associated, we used a statistical interaction test53-55 to assess if 
modeling the contribution of a cell type significantly improved the observed association 
between genotype and gene expression. Interaction tests were performed on all 
independent pairs of eGenes and corresponding lead eQTLs using liver cell type 
estimates from the high, collapsed, and low resolution as interaction terms. Overall, 
across the high, low, and collapsed resolutions we respectively detected 74, 121, and 528 
cell-type-associated eGenes (i.e., eGene is more significant considering cell type 
estimates but associated with one or more cell type(s); FDR-corrected p-values < 0.1, χ2 
test, Figure 2.6e-g) and 54, 68, and 220 cell-type-specific eGenes (i.e. eGene is 
associated with only one cell type; Figure 2.6e-g). We investigated if relative cell 
abundance influenced our ability to detect cell-type-associated eGenes (i.e., is there more 
power for high abundance cells) and determined that it did not play a factor. Further, we 
noted by using low resolution and collapsed resolution cell populations, we respectively 
detected 1.6 and 7.1 times more cell-type-associated eQTLs than high resolution cell 
populations (respectively, p = 1.9 x 10-7 and 7.3 x 10-250, Fisher’s exact test, Figure 2.6e-
g). While initially counter-intuitive to the previous evidence showing higher resolution 
eGenes are more tissue-specific (Figure 2.6b) and have decreased noise (Figure 2.6c,d), it 
is possible we identify a greater number of cell-type-associated eGenes using low 
resolution cell population estimates due to prevention of the dilution of eQTL signals 
between shared cell types, as might occur in cases where a regulatory variant has similar 
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effects across similar cell types. Overall, these results suggest that accounting for cellular 
heterogeneity between samples allows for the discovery of novel cell-type-associated 
(and cell-type-specific) eQTLs. 
 
2.3.7 eQTL analysis of deconvoluted GTEx skin confirms ability to identify cell-
type-associated regulatory variants   
To further investigate the impact of using cell populations on power to identify 
novel eGenes and cell-type-associated eQTLs, we conducted eQTL analyses using the 
GTEx tissue (skin), which includes the largest number of RNA-seq samples (Figure 
2.4b). Although we deconvoluted 860 skin RNA-seqs using signature genes from high 
resolution mouse skin scRNA-seq (6 cell types; Figure 2.4b), only 749 had corresponding 
genotypes from 510 distinct individuals. We identified 24,029 expressed genes in the 749 
skin RNA-seq samples with corresponding genotypes and performed three eQTL 
analyses: 1) without considering cell population distributions (bulk resolution); 2) 
considering high resolution mouse skin cell estimates (6 cell types; Figure 2.4c); and 3) 
considering collapsed resolution mouse skin cell estimates (3 cell types; Figure 2.4c,f). 
Using cell (high and collapsed) population distributions as covariates, respectively, we 
detected a 30% and 24% increase in eGenes with significant eQTLs (12,011 and 11,497 
compared with 9,232, Figure 2.6a). Similar to our observation in liver, we found that 
eGenes specific for the eQTL analysis performed using high and collapsed cell 
populations as covariates, respectively, had eQTLs in fewer tissues than eGenes detected 
at bulk resolution (p = 8.46 x 10-157; p = 4.12 x 10-128, Mann Whitney U test; Figure 2.6b), 
had a decreased effect size β (p = 1.81 x 10-32; p = 8.53 x 10-23, Mann Whitney U test, 
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Figure 2.6c), and had decreased standard error (SE) of β (p = 1.93 x 10-18; p = 2.04 x 10-
13, Mann Whitney U test, Mann Whitney U test; Figure 2.6d). We also observed that the β 
values for the top hit for each eGene were highly correlated between eQTLs detected 
using high and collapsed cell populations and eQTLs detected without using cell 
populations (r = 0.994; r  = 0.996). Further, at high resolution we detected 384 cell-type-
associated eGenes (FDR-corrected p-values < 0.1, χ2 test, Figure 2.6h) and 375 cell-type-
specific eGenes (FDR-corrected p-values < 0.1, χ2 test, Figure 2.6h), which were 
predominantly associated with leukocytes, while at collapsed resolution we detected 511 
cell-type-associated eGenes (FDR-corrected p-values < 0.1, χ2 test, Figure 2.6i) and 220 
cell-type-specific eGenes (FDR-corrected p-values < 0.1, χ2 test, Figure 2.6i), associated 
with both the collapsed epidermal cell population and leukocytes (Superpopulations 1 
and 3; Figure 2.4f). We hypothesize that substantially fewer cell-type-specific 
associations were observed in the high resolution epidermal cell types (epidermal cell, 
basal cell, stem cell of epidermis, outer bulge; Figure 2.6h) compared with the collapsed 
epidermal cells (Figure 2.6i), because of a dilution of signal between similar cell types. 
The relatively large number of cell-type-associated eGenes in skin compared with the 
liver could be reflective of sample size differences between the two tissue (749 and 153, 
respectively) impacting power to detect eGenes. These results show that even in eQTL 
studies using large sample sizes, accounting for cellular heterogeneity results in the 
detection of thousands more eGenes, which tend to show cell-type-associated differential 
regulation.  
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2.3.8 Colocalization identifies cell-type-associated regulatory variants are associated 
with specific skin diseases   
To explore the functional impact of the cell-type-associated eQTLs identified in 
skin, we examined their overlap with GWAS signals for skin traits and disease. From the 
UK Biobank, we extracted GWAS summary statistics for 23 skin traits where the cell 
types identified from skin scRNA-seq (Figure 2.7a) likely played a role in the traits and 
grouped them into seven categories based on trait similarity: 1) malignant neoplasms, 2) 
melanomas, 3) infections, 4) ulcers, 5) congenital defects, 6) cancer (broad definition, 
non-malignant neoplasm), and 7) unspecified skin conditions. As the three collapsed skin 
superpopulations identified the most cell-type-associated eGenes, we performed 
colocalization of the eQTLs identified using the collapsed resolution cell estimates and 
skin GWAS loci to identify shared causal variants using coloc56 and examining instances 
with PP4 > 0.5 (PP4, posterior probability of the colocalization model having one shared 
causal variant). We identified 394 variants that showed evidence of colocalization. These 
results show that we could identify hundreds of skin eQTLs that likely share a causal 
variant with skin GWAS traits. 
We next asked if skin GWAS traits were enriched for eQTLs that are associated with 
distinct cell types. We tested the enrichment of cell-type-associated eQTLs at multiple 
PP4 thresholds and found malignant neoplasms and melanomas were enriched for eQTLs 
associated with keratinocyte stem cells from the inner bulge (p = 1.13 x 10-3, p = 2.82 x 
10-4 Fisher’s Test; Figure 2.7b,c), and infections were enriched for eQTLs associated with 
leukocytes (p = 9.69 x 10-3 Fisher’s Test; Figure 2.7d). We did not observe a significant 
enrichment of cell-type-associated eQTLs in ulcers (Figure 2.7e), congenital 
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malformations (Figure 2.7f), cancer (broad definition), or unspecified skin conditions. It 
is unclear if this is to be expected, as it is possible other cell types not estimated may be 
contributing to the diseases or in the case of congenital malformations, it is possible that 
expression differences impacting congenital malformations may be functioning during 
development and not detectable in adult skin. Overall, these results suggest that GWAS 
lead variants are commonly cell-type-associated regulatory variants, indicating that onset 
or progression of human disease and traits may be controlled at the cell type level. 
We next sought to specifically examine the eGenes that most strongly colocalized 
with malignant neoplasms or melanoma (PP4 ≥ 0.8), as bulge stem cells have been 
implicated in playing a role in cancer57-62. We found six eGenes not previously associated 
with skin cancers with eQTLs significantly associated with inner bulge stem cells, 
including: 1) BRIX1, which has been found to play a role in cancer progression63; 2) 
RP11-875011.1, an antisense gene, which has not previously been implicated in cancer, 
however antisense genes are thought to contribute to the regulation of human cancers64 ; 
3) MUL1, which has been associated with the progression of human head and neck 
cancer65; 4) PMS2P3, has been implicated in affecting survival in pancreatic cancer66; 5) 
FTH1, which has been shown to be involved in regulating tumorigenesis67,68 and whose 
increased expression in keratinocytes may be in response to stress69,70; and 6) CNTN2, 
which is involved in cell adhesion and has been implicated in tumor development71,72. 
The identification of these disease-associated eGenes supports our ability to identify cell-
type-associated eQTLs whose functions are congruent with playing a role in the etiology 
of cancer. Together these results show that conducting eQTL studies accounting for 
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cellular heterogeneity can identify the likely causal cell-type-associated variants and 
genes underlying GWAS disease loci. 
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Figure 2.7 Using Colocalization of cell-type-associated skin eQTLs with skin GWAS traits 
(a) Cartoon describing the approximate organization of cell types identified in scRNA-seq from 
skin. Colors used for each cell type are used throughout Figure and described in the adjacent 
legend. (b,c,d,e,f) Line plots showing the enrichment of cell-type-associated eQTLs in various 
GWAS traits: malignant neoplasms (b), melanoma (c), infection (d), ulcers (e), and congenital 
malformations (f). Enrichment is plotted as the log(OR) (y-axis) over all probabilities of the eQTL 
signal overlapping (0 = not overlapping – 1 = completely overlapping) with the GWAS signal (x-
axis). Lines are colored following color-coding of each cell type from Figure 2.7a. 
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2.4 Discussion 
 
Human scRNA-seq data representative of all tissues in GTEx that could be used 
to deconvolute the more than 10,000 GTEx bulk RNA-seq samples does not yet exist. As 
the Tabula Muris resource of mouse scRNA-seq from 20 organs was recently released48, 
we sought to determine if mouse signature genes obtained from scRNA-seq could be 
used as an alternative for human signature genes for cellular deconvolution of GTEx 
RNA-seq samples. Using scRNA-seq from both mouse and human for two proof-of-
concept tissues (liver and skin), we derived signature genes and used these expression 
profiles to deconvolute GTEx liver and skin RNA-seq samples. In general, human and 
mouse estimates between the two proof-of-concept tissues were comparable, where 
discrepancies in cell composition estimates between the two species primarily resulted 
from technical and subtle immunological differences. Specifically, in both liver and skin, 
technical differences impact the resolution at which cellular composition can be 
estimated, including: 1) the number of cells captured and subjected to scRNA-seq; and 2) 
tissue sampling methodology. Further, differences in cell composition estimates for 
immune cells were observed most likely due to immunological differences between the 
two species. These differences highlight that high resolution scRNA-seq (more cells/cell 
types sampled from diverse zones) is key to identifying and estimating the composition 
of highly specialized and rare cell types.  For these reasons, the cell composition 
estimates we obtained from CIBERSORT using mouse-derived signature genes from 
proof-of-concept liver and skin scRNA-seq may still be missing cell types not captured in 
the Tabula Muris resource. An additional challenge we found that influenced our ability 
to compare cell composition estimates was the scRNA-seq cell annotations in human and 
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mouse skin did not use consistent naming conventions, thus it was not immediately clear 
how to compare cell estimates across the studies. We were able to overcome this 
challenge by integrating the mouse and human scRNA-seq, which allowed us to infer 
three similar superpopulations of cell types across the two species based on gene 
expression.  
To examine cellular heterogeneity across the GTEx resource, we used the 
signature genes obtained using scRNA-seq from 14 mouse tissue types to deconvolute 
6,829 GTEx RNA-seq samples mapping to 28 tissues from 14 organs. We found that 
GTEx tissues exhibit substantial cellular heterogeneity, with the number of cell types 
ranging from two in bladder to seven in brain and heart. Additionally, some of the tissues, 
including brain, colon, and left ventricle, showed highly variable proportions of estimated 
cell types between samples, contributing to intra-tissue cellular heterogeneity. Together, 
these results reveal a source heterogeneity in GTEx tissues that has not been previously 
considered and may contribute to reduced power to detect eQTLs.  
While genetic association studies performed by GTEx have identified a wealth of 
novel insights into how human genetics function across bulk tissues17, these analyses 
have not considered how cellular heterogeneity can confound these studies through 
biasing or even masking cell-type-specific signals. We found that considering cellular 
heterogeneity significantly improved eQTL analyses by increasing power to detect lower 
effect size genetic associations, as well as by identifying cell-type-specific associations 
that were masked in analyses using bulk RNA-seq data from the same samples. Further, 
we found resolution of cell heterogeneity influenced eQTL results, where considering 
high resolution estimates identified substantially more eQTLs than using lower 
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resolutions (low resolution or collapsed resolution); however, high resolution cell 
estimates identified fewer cell-type-associated genetic associations than lower 
resolutions. It is possible this decrease in associations may be due to a dilution of signal 
between similar cell types. Our observations suggest these two resolutions should both be 
used to power eQTL analyses in complementary ways: 1) high resolution estimates to 
power association analyses to discover lower effect size eQTLs; and 2) collapsed 
resolution estimates to identify cell-type associated eQTLs. We further show that cell-
type-associated eQTLs colocalize with lead variants from relevant GWAS traits, 
highlighting a potential path forward for understanding the impact of genetic variation on 
mechanisms underlying complex traits.  
Overall, we demonstrate that while efforts to generate a resource of scRNA-seq 
data from human tissues73 are in progress, QTL studies using human bulk RNA-seq data 
could utilize readily available mouse-derived signature genes to estimate cellular 
heterogeneity and optimize power to identify cell type-specific genetic associations. As 
the Tabula Muris resource does not represent all of the human GTEx tissues (28 of 53) it 
is possible that scRNA-seq resources from other mammalian species could be used to 
deconvolute the non-represented GTEx tissues. Our study further emphasizes that the 
straightforward approach of taking tissue heterogeneity into account when conducting 
genetic association studies has the potential to greatly expand our understanding of the 
functional impact of genetic variation on molecular and complex human traits. 
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2.5 Methods 
 
Mouse single cell transcriptome profiles from 14 mouse organs from Tabula Muris 
Single cell transcriptome profiles from 14 mouse organs were used in this 
study48. Briefly, transcriptome profiles were generated from three female and four male 
mice (C57BL/6JN; 10-15 month-old) from:  aorta, atrium, bladder, brain nonmicroglia, 
colon, fat, kidney, liver, mammary gland, muscle, pancreas, skin, spleen, ventricle (Table 
S1). Upon extraction of these organs from the mice, single cell transcriptomes were 
generated by first sorting by fluorescence-activated cell sorting (FACS) for specific 
populations (FACS method; SMART-Seq2 RNAseq libraries). We downloaded the 
normalized gene expression and annotated single-cell clusters from each organ as 
Seruat49 R objects  
(https://figshare.com/articles/Robject_files_for_tissues_processed_by_Seurat/5821263/1)
. 
Processing of scRNA-seq from human liver 
10X Genomics formatted BAM files from five human total liver homogenate 
samples43 were downloaded (GEO accession: GSE11546) and converted to fastq files 
using 10X bamtofastq (https://support.10xgenomics.com/docs/bamtofastq). Converted 
fastq files were then processed using cellranger count utility to generate gene expression 
count matrices, then the five processed liver samples were merged using cellranger aggr 
utility. 
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Annotation of the cell populations present in human liver scRNA-seq data 
Analysis of scRNA-seq from human liver43 were conducted following the same 
approach used to annotate mouse organs48. Cells with fewer than 500 detected genes or 
cells with fewer than 1,000 UMI were filtered from the data, resulting in 8,119 cells 
analyzed from human liver.  Gene expression was then log normalized and variable genes 
were identified using a threshold of 0.5 for the standardized log dispersion. Principal 
component analysis (PCA) was performed on the variable genes and significant PCs. 
Clustering was performed using a shared-nearest-neighbor graph of the significant PCs 
and single cells were visualized using Uniform Manifold Approximation and Projection 
(UMAP). Cell populations were then annotated based on the expression of known liver 
marker genes48.  
 
Collapsing liver cell population estimates 
To collapse similar cell populations in GTEx liver samples, we examined the 
UMAP from high resolution human liver scRNA-seq (Figure 2.1b) and compared to the 
UMAP from low resolution mouse liver scRNA-seq (Figure 2.1c) to identify 
broader/lower resolution classifications of cell types present in the liver. We identified 
populations in the human liver scRNA-seq that were similar (e.g. Hepatocyte populations 
0, 1, 3, and 4; Figure 2.1b) with a corresponding population in the mouse liver scRNA-
seq (e.g. Hepatocyte; Figure 2.1c). For populations identified in human not present in 
mouse, we did not perform any collapsing.  
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Annotation of the cell populations present in skin scRNA-seq data 
Human: Skin scRNA-seq49 gene expression data and cell annotations for 8,388 
cells were downloaded from http://dom.pitt.edu/rheum/centers-
institutes/scleroderma/systemicsclerosiscenter/database/. Cells with fewer than 200 
detected genes were filtered from the data.  Gene expression was then log normalized and 
variable genes were identified using a threshold of 0.5 for the standardized log 
dispersion. Principal component analysis (PCA) was performed on the variable genes and 
significant PCs. Clustering was performed using a shared-nearest-neighbor graph of the 
significant PCs and single cells were visualized using Uniform Manifold Approximation 
and Projection (UMAP). The single cells were then annotated using provided cell 
annotations and validated using marker gene expression. As the human skin scRNA-seq 
contained cell types belonging to various layers of the skin, whereas the mouse scRNA-
seq was enriched for epidermal cells, we extracted only the 5,670 human cells belonging 
to the epidermal layer of the skin. We then reanalyzed the subsetted data following the 
above methods by performing PCA, reclustering, and visualization using UMAP. 
 
Mouse: Tabula Muris cell annotations were confirmed by examining marker gene 
expression for epidermal cells, basal cells of the epidermis (Krt1High), stem cells of the 
epidermis (Top2aHigh), leukocytes (Lyz2High), and keratinocyte stem cells (Cd34High). 
While Tabula Muris annotated a single keratinocyte stem cell population, we reannotated 
this population by distinguishing between: 1)  inner bulge cell population exhibiting 
Dkk3High and ITGA6Low expression; and 2) outer bulge cell population exhibiting 
Fgf18High and ITGA6High expression.   
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Deconvolution of complex tissues using CIBERSORT 
Identification of signature genes from single cell populations: For 16 scRNA-seq 
datasets from human liver, human skin, and scRNA-seq from 14 mouse organs, we 
obtained gene expression signatures for each annotated cell type and used as input into 
CIBERSORT16 to estimate the cellular composition of GTEx adult tissues (Table 2.1).  
For each tissue, we identified differentially expressed genes using Seurat FindMarkers 
and then extracted the top 200 most significantly overexpressed genes (adjusted p-value < 
0.05; average log2 fold change > 0.25) for each of the annotated scRNA-seq cell types 
(gene expression signatures). For signature genes obtained from mouse scRNA-seq, we 
converted the mouse genes to their human orthologs using the biomaRt database74,75. The 
final gene signature sets only included mouse signature genes that also had a human 
ortholog. For a given signature gene set: 1) if a mouse gene had more than one human 
ortholog, only one human ortholog was retained in final signature set; and 2) if different 
mouse genes corresponded to the same human ortholog, only unique human orthologs 
were retained in the final signature set.  
 
Cell composition estimation: The mean expression levels of the signature genes 
were used as input for CIBERSORT to calculate the relative distribution of the cell 
populations of 28 GTEx tissues from 14 organs. CIBERSORT 
(https://cibersort.stanford.edu/) was run with default parameters using the TPM values for 
the signature genes identified from scRNA-seq in all RNA-seq samples from the 
analogous GTEx tissue (https://gtexportal.org/home/datasets) (Table 2.1). To determine 
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the cell types detected in GTEx compared to the cell types modeled from mouse, we 
classified a given cell type as estimable in GTEx as those with CIBERSORT estimates 
greater than 0.05% in more than 5% of RNA-seq samples from a given GTEx tissue. To 
estimate cellular heterogeneity across GTEx RNA-seq samples, heterogeneity was 
measured as the average square distance from the mean for each GTEx tissue. We further 
examined how time from death or withdrawal of life-support until each tissue sample was 
fixed/frozen (i.e. ischemic time) is associated with cellular heterogeneity and we did not 
observe a consistent trend between ischemic time and cellular heterogeneity. GTEx 
organs are defined as the regions from which tissues are sampled (variable name SMTS 
from sample attributes data table; phv00169239.v7.p2) and GTEx tissues are defined by 
the distinct area of the organ where the tissue was taken (variable name SMTSD from 
sample attributes data table; phv00169241.v7.p2). For example, samples from the GTEx 
organ, colon, is comprised of two tissues: sigmoid colon and transverse colon. 
 
Harmonization of human and mouse scRNA-seq 
To harmonize scRNA-seq from human and mouse liver and skin, mouse genes 
for each tissue scRNA-seq dataset were first converted to their human orthologs using the 
BioMart database74,75. Mouse and human scRNA-seq were then harmonized by 
identifying genes that anchor the two datasets using Seurat FindIntegrationAnchors and 
using these anchors to integrate the datasets using Seurat IntegrateData. Integrated 
datasets were then visualized using UMAP and corresponding cell types were identified 
by examining overlap of mouse and human cells.  
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Detecting eQTLs using a linear mixed model 
To detect eQTLs, we obtained gene TPMs for 153 liver bulk RNA-seq samples 
and 749 skin bulk RNA-seq samples (sun-exposed and not sun-exposed) from the GTEx 
V.7 website (https://gtexportal.org/home/) and downloaded WGS VCF files from dbGaP 
(525 individuals, phs000424.v7.p2). Only genes with TPM > 0.5 in at least 20% samples 
were considered (19,621 genes in liver and 24,029 in skin). Gene expression data was 
quantile-normalized independently for each tissue type. For all eQTL analyses, we used 
the following covariates: age, sex and the first five genotype principal components (PCs) 
calculated using 90,081 SNPs in linkage equilibrium19. Since some subjects had two skin 
samples (one sun-exposed and one not sun-exposed), we employed a linear mixed model 
(LMM) for eQTL detection, using subject ID as random effect (1|subject_id). We fitted 
LMMs using the lme4 package (https://www.jstatsoft.org/article/view/v067i01/0)) to 
detect eQTLs in skin, described in the following model55: 
Expression ~ genotype + covariates + (1|subject_id) 
For liver, we used sex as random effect (1|sex) to fit an LMM analogous to the skin 
eQTL analysis method, described in the following model: 
Expression ~ genotype + covariates + (1|sex) 
We calculated associations with all variants (minor allele frequency > 1%) ± 1 
Mb around each expressed gene. For each gene, we Bonferroni-corrected p-values and 
retained the lead variant. To detect eGenes, we used Benjamini-Hochberg FDR at 10% 
level on all lead variants.  
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Improved eQTL detection using cell population distributions as covariates 
We repeated eQTL detection adding cellular compositions as covariates to the 
LMMs described above using the following model: 
expression ~ genotype + covariates + cell_populations + (1|random) 
The “cell_populations” term denotes the relative cell population distributions in each 
tissue and (1|random) is each tissue’s random effect (1|subject_id in skin samples; 1|sex 
in liver samples, see: Detecting eQTLs using a linear mixed model).  
Specifically, we conducted three eQTL analysis for the liver using human high 
resolution, human collapsed and mouse low resolution cell populations as covariates. 
Since several cell types were detected at very low frequency, we only used a subset of the 
cell types described in Figure 2.5: 1) for human high resolution: periportal sinusoidal 
endothelial cells, central venous endothelial cells, gdT cells, hepatocytes0, hepatocytes3, 
hepatocytes4, inflammatory macrophages and NK/NKT cells; 2) for human collapsed 
resolution: endothelial cells, hepatocytes, macrophages, NK cells, B cells, 
cholangiocytes, and heptatic stellate cells; and 3) for mouse low resolution: endothelial 
cells of hepatic sinusoid, hepatocytes, Kupffer cells and NK cells. We conducted two 
eQTL analysis for skin using mouse high and mouse collapsed resolution cell populations 
as covariates with the following cell populations: 1) for mouse high resolution: epidermis 
stem cell, leukocyte, inner bulge, outer bulge, epidermis, and epidermis basal cells; and 
2) for mouse collapsed resolution: epidermal cells, leukocyte, and inner bulge cells.  
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Detecting cell-type-specific and cell-type-associated eQTLs 
In order to detect eQTLs associated with one or more cell types, for each cell 
population we repeated the eQTL analyses described above (see: Improving eQTL 
detection using cell population distributions as covariates) by adding an interaction term 
between the genotype and each cell population (celli) estimate to the model 
(genotype:celli). Specifically, for each celli estimate, we compared the following two 
models: 
H0: expression ~ genotype + covariates + cell_populations + (1|random) 
H1: expression ~ genotype + covariates + cell_populations + genotype:celli + 
(1|random) 
In both models (H0 and H1), the “cell_populations” term denotes the relative cell 
population distributions in each tissue and (1|random) is each tissue’s random effect 
(1|subject_id in skin samples; 1|sex in liver samples, see: Detecting eQTLs using a linear 
mixed model). In H1, “genotype:celli” is the interaction term between the genotype and 
celli estimate. 
To compare the two hypotheses (H0 and H1), we calculated the difference 
between the two models using ANOVA and obtained χ2 p-values using the pbkrtest 
package. For each celli estimate used as an interaction term in H1, only eGenes that 
satisfied two requirements were considered to be associated with celli: a) Benjamini-
Hochberg-adjusted χ2 p-value <0.1; and b) ∆𝐴𝐼𝐶= 𝐴𝐼𝐶𝑖𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛 − 𝐴𝐼𝐶𝑛𝑜 𝑖𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛 < 0 
(i.e. “genotype:celli” interaction terms that significantly improve the eQTL model). If 
only one cell population improved the eQTL model, the eQTL was labeled “cell-type 
specific”; conversely, if more than one cell population improved the eQTL model, the 
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eQTL was labeled “cell type-associated”. We determined the impact of cell population 
abundance on power to detect cell-type-associated eGenes by examining the distribution 
of ß, standard error, and P-value for cell-type-associated-eQTLs from each cell 
population. 
 
Permutation analysis of liver eQTLs  
To test if the detection of more eQTLs using cell populations as covariates was 
due to improved accuracy of the linear mixed model estimation or was simply associated 
with an increased number of covariates, for each top hit (defined as the variant with the 
strongest p-value for each gene), we permuted the cell type distribution across samples, 
1,000 times. We obtained the average p-value, beta and standard error of beta across all 
permutations and compared these values with the measured p-value, beta and standard 
error of beta for each gene using a paired t-test.  
 
Colocalization of UK Biobank GWAS for skin traits and eQTLs identified from skin  
For each eGene in the skin eQTL analysis deconvoluted using cell type 
estimates, we extracted the p-values for all variants that were used to perform the eQTL 
analysis. From the UK BioBank, we obtained summary statistics for 23 skin-related 
traits, where the traits were grouped into seven categories based on shared nomenclature 
in the trait descriptions: 1) malignant neoplasms; 2) melanoma; 3) infection; 4) ulcers; 5) 
congenital malformations of the skin; 6) other cancer (non-melanoma or malignant 
neoplasm); and 7) unspecified. For all the variants genotyped in both GTEx and UK 
BioBank, we used coloc V. 3.156 to test for colocalization between eQTLs and GWAS 
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signal. For each colocalization test, we considered only the posterior probability of a 
model with one common causal variant (PP4). Enrichment of the associations was 
calculated using a Fisher’s Test at multiple PP4 thresholds (0 – 1; by 0.05 bins), where 
the contingency table consisted of two classifications: 1) if the variant was significantly 
cell-type-associated (FDR < 0.05); and 2) if the variant colocalized with the GWAS trait 
greater than each PP4 threshold. 
 
2.6 Data Availability 
 
Sequence data that support the findings of this study (all Figures) is available for 
human liver scRNA-seq (GSE11546); for human skin scRNA-seq 
(http://dom.pitt.edu/rheum/centers-
institutes/scleroderma/systemicsclerosiscenter/database/); and for Tabula Muris mouse 
scRNA-seq 
(https://figshare.com/articles/Robject_files_for_tissues_processed_by_Seurat/5821263/1)
. Scripts to process, analyze, and generate Figures from the data is available at 
https://github.com/mkrdonovan/gtex_deconvolution. The source data underlying all 
Figures is available in the Source Data available online. 
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